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Abstract  
Objective and background. Activation of sterile inflammation after hepatic I/R culminates in liver injury. 
The route to liver damage starts with mitochondrial oxidative stress and cell death during early 
reperfusion. The link between mitochondrial oxidative stress, damage-associate molecular pattern 
(DAMP) release, and sterile immune signalling is incompletely understood and lacks clinical validation. 
The aim of the study was to validate this relation in a clinical liver I/R cohort and to limit DAMP release 
using a mitochondria-targeted antioxidant in I/R-subjected mice. 
Methods. Plasma levels of the DAMPs high-mobility group box 1 (HMGB1), mitochondrial DNA, and 
nucleosomes were measured in 39 patients enrolled in an observational study who underwent a major 
liver resection with (N=29) or without (N=13) intraoperative liver ischemia. Circulating cytokine and 
neutrophil activation markers were also determined. In mice, the mitochondria-targeted antioxidant MitoQ 
was intravenously infused in attempt to limit DAMP release, reduce sterile inflammation, and suppress I/R 
injury. 
Results. In patients, HMGB1 was elevated following liver resection with I/R compared to liver resection 
without I/R. HMGB1 correlated positively with ischemia duration and peak post-operative transaminase 
(ALT) levels. There were no differences in mitochondrial DNA, nucleosome, or cytokine release. In mice, 
MitoQ neutralized hepatic oxidative stress and decreased HMGB1 release by ±50%. MitoQ suppressed 
transaminase release, hepatocellular necrosis, and cytokine production. Reconstituting disulfide HMGB1 
during reperfusion reversed these protective effects. 
Conclusion. HMGB1 seems the most pertinent DAMP in clinical hepatic I/R injury. Neutralizing 
mitochondrial oxidative stress may limit DAMP release after hepatic I/R and reduce liver damage. 
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Abbreviations: 
ALT = alanine aminotransferase 
ASA = American Society of Anesthesiologists 
AST = aspartate aminotransferase 
BMI = body mass index 
CTRL = control (group) 
CRC = colorectal cancer metastasis 
DAMP = damage-associated molecular pattern 
dTPP = decyl-triphenylphosphonium  
HCC = hepatocellular carcinoma 
HMGB1 = high-mobility group box 1 
I/R = ischemia/reperfusion 
ICAM = intercellular adhesion molecule  
IHC = intrahepatic cholangiocarcinoma 
IL = interleukin 
INR = international normalized ratio 
IQR = interquartile range 
mtDNA = mitochondrial DNA 
PHCC = perihilar cholangiocarcinoma 
PVE = portal vein embolization 
RAGE = receptor for advanced glycation end products 
ROS = reactive oxygen species 
TLR = toll-like receptor 
NAC = N-acetylcysteine 
VIO = vascular inflow occlusion 
VCAM = vascular cell adhesion protein  
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1. Introduction 
During major liver resection, the induction of liver ischemia by surgical clamping of the afferent hepatic 
vasculature is used to counter the risks of excessive blood loss. This surgical technique is known as 
vascular inflow occlusion (VIO) or the Pringle maneuver
1
. When employed within predefined time limits 
and in selected patients, this manoeuvre is considered safe. However, the transient lack of organ 
perfusion and oxygenation also inadvertently causes ischemia/reperfusion (I/R) injury
2-4
 and the severity 
of hepatic I/R injury impacts the recovery of patients after major liver surgery.  
 Activation of sterile inflammation is a key feature of hepatic I/R injury. During ischemia, the lack of 
oxygen halts oxidative phosphorylation and leads to the build-up of citric acid cycle metabolites such as 
succinate
5,6
. Once the oxygen supply is restored, the consumption of accumulated succinate during the 
first minutes of reperfusion fuels a burst of reactive oxygen species (ROS) production by the 
mitochondrial electron transport chain
5,6
. The consequent wave of ROS-induced cell death triggers the 
release of damage-associated molecular patterns (DAMPs) by hepatocytes. DAMPs are innocuous 
intracellular constituents that become potent triggers of the innate immune system once released into the 
circulation
2,7
. Effector cells of the innate immune system such as neutrophils in turn confer the bulk of 
hepatic tissue injury. Based on this sequence of events, DAMPs occupy a crucial role in the onset of I/R 
injury as signal transducers and amplifiers of the sterile immune response. 
 Several DAMPs, including histones
8
, DNA
9
, and high-mobility group box 1 (HMGB1)
10
 have been 
causally linked to hepatic I/R injury in animal studies. DAMP release has also been measured in clinical 
accounts of sterile liver injury
11,12
. However, the link between mitochondrial oxidative stress and DAMP 
release has not been clinically elaborated in the context of hepatic I/R injury to date, and was therefore 
investigated in this study. To that end, DAMP release was studied in patients undergoing liver resection 
with or without being subjected to I/R.   
 It is shown that patients who underwent major liver surgery rapidly exhibit DAMP release after 
resection. Of the tested DAMPs, only HMGB1 levels increased specifically in I/R-subjected patients and 
not in the control group operated without I/R. HMGB1 release correlated positively with ischemia time and 
postoperative hepatocellular injury markers. The results were back-translated to a validated mouse 
model
13
 to allow experimental confirmation and further elaboration. Decreasing mitochondrial oxidative 
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damage during early reperfusion with the mitochondria-targeted antioxidant MitoQ in mice prevented 
HMGB1 release and attenuated the I/R immune response. Decreasing mitochondrial oxidative damage 
therefore may potentially improve outcomes in patients undergoing major liver surgery. 
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2. Materials and methods 
 
 
References to the supplemental information are indicated with the prefix ‘S’.  
 
2.1 Study participants and study design 
The effect of liver surgery performed with or without intraoperative liver ischemia on DAMP release was 
investigated in a single-center observational trial registered at https://ClinicalTrials.gov under identifier 
NCT01700660. Eligible for participation were all patients scheduled for a major liver resection (removal of 
≥3 Couinaud segments) that were ≥18 years old and had an American Society of Anesthesiology physical 
status score of 3. Patients were excluded from the study when considered unresectable during surgical 
exploration, when the employed ischemia time was <20 min, when they underwent an emergency 
operation, or when the patient was pregnant or breast-feeding. Because the decision whether or not to 
use vascular inflow occlusion (VIO) and thereby subject patients to I/R was made at the discretion of the 
performing surgeon based on the actual or anticipated amount of blood loss, participants were non-
randomly assigned to either the I/R group (N=26) or the control group (N=13). Intermittent VIO was 
typically performed in cycles comprising 20 min of ischemia followed by 10 min of reperfusion. In a minor 
fraction of patients, the operative cause necessitated the use of continuous VIO (see Supplemental Table 
S4).  All patients were operated by the same primary surgeon (TVG).  
 Blood samples were drawn from a central venous catheter after the induction of general 
anesthesia (i.e., at baseline) and 1 and 6 h after the start of reperfusion (I/R group) or completion of 
parenchymal transection (CTRL group). Plasma liver injury (ALT) and liver function (international 
normalized ratio (INR), total bilirubin) were determined as part of routine patient care. Post-operative 
complications were categorized according to the Clavien-Dindo grading system
14
. All experimental results 
were normalized to plasma protein content (Pierce BCA Protein Assay Kit, Life Technologies, Carlsbad, 
CA) to correct for hemodilution, as described
15
. All study protocols ware approved by the Institutional 
Review Board and written informed consent was obtained from all participants before undergoing any 
study-related procedures. The study design is summarized in Supplemental Figure S1. 
 
2.2 Circulating HMGB1  
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Plasma HMGB1 levels were determined in 10 L of EDTA-anticoagulated plasma samples by ELISA (IBL 
International, Hamburg, Germany) according to manufacturer’s instructions. All samples were measured 
in duplicate in regular sensitivity mode on a Synergy HT microplate reader (BioTek Instruments, 
Winooski, VT). 
 
2.3 Circulating nucleosomes and elastase-1-antitrypsin complexes 
Nucleosome levels were assessed by ELISA as previously described
16
. Briefly, monoclonal antibody 
CLB-ANA/60 (Sanquin, Amsterdam, the Netherlands) that recognizes histone 3 was used as capture 
antibody. Biotinylated F(ab)2 fragments of monoclonal antibody CLB-ANA/58 (Sanquin), which 
recognizes an epitope exposed on complexes of dsDNA histone 2A and histone 2B in combination with 
poly-horseradish peroxidase–labeled streptavidin (Sanquin) were used for detection. As a standard, we 
used culture supernatant of Jurkat cells (1×10
6
 cells/mL), cultured for an additional week without 
refreshing the medium, to obtain 100% apoptotic cells. One unit is the amount of nucleosomes released 
by ≈100 Jurkat cells. The lower detection limit of the assay was 2.5 U/mL
17
. The reference range for 
circulating nucleosomes in healthy individuals is 0-10.3 U/mL. 
 Elastase-1-antitrypsin complexes (E-AT) were measured by ELISA as described
18
. This assay 
was adapted from a previously described radioimmunoassay
19
. Briefly, plates were coated with a 
polyclonal rabbit anti-human neutrophil elastase antibody (1.5 μg/mL; Sanquin). Standard and samples 
were diluted in high-performance ELISA buffer (HPE; Sanquin) + 40 μg/mL bovine IgG. Bound complexes 
were detected with a biotinylated monoclonal anti–α1 -antitrypsin antibody (1 μg/mL; Sanquin) in 
combination with poly-horseradish peroxidase–labeled streptavidin. Results are expressed in ng/mL by 
reference to a standard curve of normal human citrated plasma in which EA-T were generated by 
incubation with porcine elastase (final concentration 2 μg/mL; Sigma, Zwijndrecht, the Netherlands) for 15 
min at room temperature. The detection limit of the assay was 2 ng/mL. The reference range for EA-T in 
healthy individuals is 8.5 to 55.7 ng/mL. 
 
 
2.4 Circulating mitochondrial DNA   
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Plasma mitochondrial DNA levels were determined according to Nakahira et al.
20
, with minor 
modifications. Total DNA was isolated from 190 μL of heparin-anticoagulated plasma using the QIAamp 
DNA Blood Mini Kit (cat. #51106, Qiagen) according to the manufacturer’s instructions. DNA was eluted 
in 100 μL of elution buffer. Levels of mitochondrial DNA (mtDNA) were analyzed in duplicate by real-time 
quantitative PCR on a Lightcycler 480 (Roche) using a reaction volume of 10 L consisting of 2 L of 
DNA, 2 L of nuclease-free water (Qiagen), 1 L of primer mix (0.5 M final primer concentration), and 5 
L of SensiFAST SYBR No-ROX mix (Bioline, London, UK). The run parameters are specified in 
Supplemental Table S1. The following primers were used: human mitochondrially-encoded NADH 
dehydrogenase 1 (MT-ND1): forward 5’-ATACCCATGGCCAACCTCCT-3’, reverse 5’-
GGGCCTTTGCGTAGTTGTAT-3’
12
. Melting curve analysis and ethidium bromide-stained agarose gel 
electrophoresis were used to validate primer specificity. A plasmid encoding a human cDNA clone of MT-
ND1 was purchased from ORIGENE (SC101172) and was used as a logarithmic mtDNA standard in 10-
fold serial dilutions (1.93 x 10
6
 copies – 1.93 x 10
0
 copies). Data were processed according to Ruijter et 
al.
21
, fitted to the mtDNA standard, and normalized to plasma protein content. 
 
2.5 Human plasma cytokine measurements 
L-12p70, TNF, IL-10, IL-6, IL-1, and IL-8/CXCL8 concentrations were determined in serum samples 
using the Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit (BD Biosciences, Franklin, 
NJ) according to the manufacturer's instructions. The samples were analyzed in a blinded fashion and 
flow data were collected using a BD FACSCanto II (BD Biosciences). The results were analyzed with 
FCAP Array version 3.0 software (BD Biosciences). CCL2 plasma concentration was measured by ELISA 
(Duosets, R&D Systems, Minneapolis, MN). All reagents and solutions were prepared fresh each week 
according to the manufacturer’s protocols and were sterile filtered using 0.2 μM bottle-top vacuum filters 
(Corning, Corning, NY). Bovine serum albumin was of the highest available purity (cat. #A7030, Sigma-
Aldrich, St. Louis, MO) and ELISAs were performed using clear 96-well flat bottom polystyrene 
microplates (#9018, Corning). All cytokine levels were normalized to plasma total protein content.  
 
2.6 Mouse hepatic ischemia/reperfusion experiments 
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The animal experiments were approved by the institute’s animal welfare committee and surgical 
procedures were as described
13
. MitoQ was dissolved to a concentration of 6 mg/mL MitoQ in sterile NaCl 
(Braun). After induction of anesthesia, 250 ng/kg – 3 mg/kg MitoQ or an equimolar amount of the inactive 
targeting moiety decyl-triphenylphosphonium (dTPP) in sterile NaCl was infused via the penile vein in a 
volume of 100 L per 30 g body weight. After allowing MitoQ or dTPP to circulate for 10 min, partial (70%) 
liver ischemia was induced for 30 min
13
. As a control group, animals underwent sham surgery that 
entailed a laparotomy with mobilization of hilar structures, but without actual occlusion of the afferent 
vasculature. For every set of experiments, animals were randomly assigned to an experimental arm. For 
HMGB1 reconstitution experiments, 2.5 g disulfide HMGB1 (IBL) in 100 L sterile NaCl was 
administered intraperitoneally immediately after reperfusion was initiated. Disulfide HMGB1 was selected 
for the reconstitution experiments because (1) it is the predominant isoform released in mice subjected to 
hemorrhagic shock and resuscitation
22
 - a model that pathophysiologically resembles liver I/R - and (2) 
the disulfide isoform activates the hepatic I/R-pertinent TLR-4 signaling axis
10,23,24
. Animals were 
sacrificed at 6 h or 24 h of reperfusion. Blood and liver samples were processed as described
13
. The 
number of animals per group per experiment is included in the figure legends. To account for variations in 
experimental conditions and animal batches, a new control group of vehicle-treated mice subjected to I/R 
was included in every new set of experiments.  
 
2.7 Mouse liver histology  
Mouse liver specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin and 
eosin as described
13
. The extent of confluent parenchymal necrosis was scored by a hepatopatoholigst 
(JV) according to the following grading system: 0=no necrosis, 1=<25% necrosis, 2=25-50% necrosis, 
3=50-75% necrosis, and 4=>75% necrosis. 
 
2.8 Western blot  
Frozen liver (-80 
o
C) samples were homogenized with an Omni Tissue Master 125 (Omni International, 
Kennesaw, GA) in cell lysis buffer (50 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% 
glycerol, 0.1% Triton X-100 containing protease and phosphatase inhibitors). Cell debris was pelleted 
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(12,000 x g, 5 min), supernatant protein content determined (DC Protein Assay, Bio-Rad), and SDS-
polyacrylamide gel electrophoresis (Bio-Rad Mini-PROTEAN) was performed with samples standardized 
to 30 µg protein/well. Proteins were separated using 7.5% gels, followed by electrophoretic elution onto 
PVDF membranes (Trans-Blot Turbo, Bio-Rad), as per manufacturer’s instructions. Blots were run under 
reducing conditions. PVDF membranes were blocked (5% skim milk, 1 h), incubated with primary 
antibodies (Supplemental Table S1) for 16 h (4 
o
C) and stained with appropriate HRP-conjugated 
secondary antibodies (Santa Cruz). Immunoreactivity was detected using SuperSignal West Femto 
Substrate (Thermo Scientific) and digital chemiluminescence image capture (LAS-4000, FujiFilm, Tokyo, 
Japan). Densitometric analysis was performed with MultiGauge software (V3.0, FujiFilm, Tokyo, Japan), 
and all values were normalized to the expression of the housekeeping protein -actin. All experiments 
were performed in triplicate. 
 
2.9 Mouse plasma cytokine measurements 
Mouse plasma samples were assayed for mouse GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL12p70, IL-
13, IL-18, and TNF- using the ProcartaPlex Mouse Th1/Th2 extended 11-plex kit and mouse BAFF, IL-
10, IL-22, RANTES/CCL5, TSLP, and VEGF-A using ProcartaPlex simplex kits on the Luminex platform 
(Affymetrix, Santa Clara, CA), according to the manufacturer’s instructions. The relevance of these 
inflammatory messengers for hepatic I/R injury is summarized in Supplemental Table S3. In brief, 
samples were thawed on ice. The antibody-coated beads were mixed and washed, and incubated 
overnight at 4 °C with 1:1 diluted standards or samples. After washing, the beads were incubated with 
detection antibody mix for 30 min at room temperature. The beads were subsequently washed and 
incubated for 30 min at room temperature with streptavidin-PE. After washing, the beads were measured 
with a Luminex instrument (Bio-Plex 200, Bio-Rad) that was calibrated using Bio-Rad calibration beads. 
Standard curves were calculated using 5-parameter logistic regression in Bioplex 5.0 software. Heatmaps 
were generated using GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-E/) and 
show the plasma cytokine levels of MitoQ-treated mice following 30 min of ischemia and 6 h or 24 h of 
reperfusion. Data per time point are expressed as fold-increase compared to the mean of the vehicle 
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control group, whereby blue indicates a decrease and red indicates an increase in the MitoQ group 
versus control animals subjected to I/R only.  
 
2.10 Intravital imaging and spectroscopic quantification of reactive oxygen species production during 
hepatic I/R injury in mice 
The oxidation-sensitive fluorogenic probe 5(6)-carboxy-dichlorodihydrofluorescein was prepared from 
5(6)-carboxy-dichlorodihydrofluorescein diacetate and encapsulated in hepatocyte-targeted liposomes 
according to Reiniers et al
25
. Liposomes (0.1 mol lipid/g body weight in 200 L 10 mM HEPES, 0.88% 
NaCl, 0.292 osmol/kg, pH = 7.4) were injected via the penile vein and circulated for 35 min to allow 
intrahepatic accumulation. Hepatic I/R was subsequently performed as described
25
. To perform the 
surgical procedure with the mice positioned under the intravital imaging setup, ischemia was induced with 
a silicone sling placed around the hepatic pedicle instead of a microvascular clamp. During the first 10 
min of reperfusion, hepatic probe conversion was quantified at 2-min intervals in real-time using a 
customized intravital fluorescence microscope (M165FC, Leica Microsystems, Wetzlar, Germany) 
equipped with a spectrometer (QE65000, Ocean Optics, Dunedin, FL). Spectroscopic data were 
integrated over the entire spectral width ( = 250–1050 nm) and normalized to baseline.  
 
2.11 Statistical analyses 
Statistical analyses were performed using Graphpad Prism 6 (La Jolla, CA) and SPSS 21.0 (Chicago, IL), 
abiding by a significance level (α) of 0.05 unless otherwise indicated. Normal distribution of data sets with 
8 values was assessed using a D’Agostino and Pearson omnibus test. Normally distributed data were 
tested for intragroup and intergroup differences using a student’s t-test, a one-way ANOVA with Dunnet’s 
post-hoc test, or a repeated measure ANOVA with Geisser-Greenhouse correction and Tukey’s post-hoc 
correction. All continuous numerical variables that failed the normality test were log transformed and re-
analyzed. Log-transformed data that followed a Gaussian distribution were analyzed parametrically as 
described. If the transformed data failed the normality test, non-parametric tests (Mann Whitney U, 
Kruskall-Wallis with Dunn’s post-hoc test, or Friedman with Dunn’s correction) were performed on the 
non-transformed data. Data sets with <8 values group were tested parametrically. Categorical data were 
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analyzed using a Fisher’s exact test (binary data) or a Chi-squared test (>2 variables) and correlations 
were tested using Spearman’s rho.   
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3. Results 
 
3.1 DAMP release after major liver resection in patients 
To study DAMP release after clinical liver I/R, a total of 74 patients were enrolled in an observational 
study. Of the 74 study participants, 35 were excluded due to unresectable disease during surgical 
exploration (N=30), withdrawal of consent (N=1), an unanticipated change in primary surgeon (N=1), or 
because a minor instead of a major liver resection was performed (N=3). The relationship between 
hepatic I/R injury and DAMP release was therefore studied in 39 patients who underwent a major liver 
resection with (N=26, ‘I/R’) or without (N=13, ‘CTRL’) the intraoperative use of VIO. The study design is 
summarized in Supplemental Figure S1. The baseline patient characteristics are shown in Table 1 and 
the clinical outcomes are presented in Table 2. 
 The baseline patient characteristics were comparable between the two study arms. VIO use was 
associated with longer operating time, resection time, and hospital stay compared to the control group 
(Table 2). A trend towards more extensive liver resection was seen in the I/R group (Table 2). The 
severity of postoperative liver injury did not differ between the groups when judged by liver damage (i.e. 
the postoperative ALT peak) or liver function parameters such as INR and bilirubin (Table 2). There were 
also no differences in transfusion requirements, postoperative complications, or mortality between the 
control and I/R group (Table 2). As the aim of the study was to explore DAMP release and activation of 
sterile inflammation in I/R-subjected patients, it should be underscored that the study was neither 
designed nor powered to detect differences in patient outcomes between the control and I/R group.  
 Systemic DAMP levels were next determined in the full cohort at baseline and at 1 h and 6 h after 
surgery. HMGB1 and nucleosomes were assessed based on preclinical hepatic I/R work
8,24
. Circulating 
mitochondrial DNA (mtDNA) was assayed because hepatic I/R injury is thought to originate in ROS-
generating mitochondria
5
 and because mtDNA release has been documented in both animal and clinical 
studies on sterile liver injury
11,12
. Figure 1A-B show that systemic HMGB1 and nucleosomes 
concentrations increased within 1 h after surgery in the combined cohort, which was accompanied by a 
rise in neutrophil activation (Fig. 1D). Systemic mtDNA levels remained unchanged during the first 6 h of 
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reperfusion (Fig. 1C). These data show that the DAMPs HMGB1 and nucleosomes are released into the 
circulation after major liver resection.  
To determine whether DAMP release was caused by ischemia-mediated hepatocyte injury or by 
surgical trauma per se, which has been noted previously
26
, the patient data were stratified into an I/R and 
a control group. Figure 2A-D show that, of the tested DAMPs, only HMGB1 levels increased significantly 
at 1 h of reperfusion in the I/R group but not in the control group. The release of the cytokines interleukin 
(IL)-1 and IL-6 was also more pronounced in the I/R group than in the control group at 1 h of reperfusion 
(Fig. S2). The early intergroup differences in HMGB1 and cytokine release resolved 6 h after surgery (Fig. 
2A, S2). Nucleosome release and neutrophil activation were comparable between groups at all time 
points (Fig. 2B-C).  In line with the release of HMGB1 in only the I/R group, systemic HMGB1 levels after 
surgery correlated positively to the postoperative ALT peak (Fig. 2E) and the used duration of hepatic 
ischemia (Fig. 2F). Such a relationship was typically absent for cytokine levels or neutrophil activation 
(Fig. S3). Collectively, these results suggest that HMGB1 is the DAMP that is most pertinent to clinical 
hepatic I/R injury.  
 
3.2 Neutralizing mitochondrial oxidative stress limits HMGB1 release after mouse liver I/R 
After establishing that HMGB1 is released in patients after hepatic I/R, the therapeutic efficacy of 
inhibiting HMGB1 release was investigated in a validated mouse hepatic I/R model
13
.  
Because mitochondrial oxidative injury is considered the most proximal trigger of I/R injury and therefore 
may cause the release of DAMPs, it was tested whether the mitochondria-targeted antioxidant MitoQ 
could limit HMGB1 release and, thereby, attenuate hepatic I/R injury in mice. The cytoprotective efficacy 
of MitoQ was established first. The intravenous administration of MitoQ reduced plasma ALT levels at 6 h 
and 24 h of reperfusion in mice over a 0.25-1 mg/kg dose range (Fig. 3A), whereas non-specific MitoQ 
toxicity was seen at higher dosages. Based on this pharmacodynamic profile, 1 mg/kg of MitoQ was used 
in all in vivo experiments.  
 In concordance with a previous report demonstrating the antioxidant efficacy of MitoQ in I/R-
subjected mice
27
, MitoQ reduced oxidation of the fluorogenic probe 5(6)-carboxy-dichlorofluorescein in 
hepatocytes during the first 10 min of reperfusion, as measured by intravital spectroscopy (Fig. 3B). The 
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fluorogenic probe was delivered specifically to hepatocytes using a hepatotargeted delivery system
25
. 
MitoQ did not affect the number of leukocytes in the hepatic microcirculation during the first 90 min of 
reperfusion (Fig. S6, S7). The early reduction in oxidative stress (Fig. 3B) translated to a drop in 
hepatocellular necrosis and transaminase release at 24 h of reperfusion (Fig. 3C-D), indicating a 
reduction in hepatic I/R injury. Animals that received the inactive targeting moiety of MitoQ, dTPP, were 
not protected from I/R injury (Fig. 3C-D), reaffirming that the antioxidant properties of the ubiquinol moiety 
convey the hepatoprotective effects of MitoQ. 
 After demonstrating that MitoQ was able to reduce I/R injury, the effect of neutralizing 
mitochondrial oxidative stress on HMGB1 release after mouse liver I/R was explored. Figure 3E shows 
that MitoQ reduced plasma HMGB1 levels after I/R by approximately 50% at 6 h of reperfusion. 
Quantification of HMGB1 in liver biopsies by Western blot showed similar HMGB1 levels in MitoQ-treated 
and untreated mice subjected to I/R (Fig. 3F). This finding may relate to differences in resolving capacity 
between the techniques used for plasma and whole-liver HMGB1 quantification. To examine whether 
HMGB1 release was associated with the documented hepatoprotective effect of MitoQ, DAMP 
reconstitution experiments were performed. Infusing the pro-inflammatory disulfide isoform of HMGB1
28
 at 
the start of reperfusion nullified the protective potential of MitoQ (Fig. 3G), which supports the hypothesis 
that I/R injury sequentially proceeds via mitochondrial oxidative injury and DAMP release.  
 Systemic HMGB1 alerts the immune system via the receptor for glycation end products (RAGE) 
and/or Toll-like receptor 4 (TLR-4)
24,29
, which drive cytokine production by activating various pro-
inflammatory transcription factors. After establishing that neutralizing mitochondrial oxidative stress with 
MitoQ decreased HMGB1 release and reduced hepatic I/R injury, it was determined whether MitoQ 
treatment also attenuated inflammatory signaling following mouse liver I/R. Levels of chemotactic and 
cytotoxic messengers such as tumor necrosis factor (TNF-) and interleukin (IL-)1 were lower in the 
MitoQ group at 6 h of reperfusion, whereas a stronger induction of anti-inflammatory IL-10 was noted at 
the 24 h time point (Fig. 3J). This favorable effect of MitoQ on cytokine profiles may have resulted in the 
downregulation of the leukocyte receptor VCAM-1, even though the expression of the principal sinusoidal 
neutrophil receptor ICAM-1 was unaffected (Fig. 3HI).  
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4. Discussion  
This study shows that (i) the DAMP HMGB1 seems most pertinent in clinical liver I/R injury, (ii) that 
HMGB1 levels positively correlate with liver injury markers in I/R-subjected patients, and (iii) that treating 
mitochondrial oxidative injury with MitoQ prevents HMGB1 release and consequent sterile inflammation, 
ultimately attenuating I/R injury in mice.  
 Major liver resection remains associated with considerable mortality, exceeding 10% in patients 
with high-risk tumors
30
. The ramifications of liver ischemia therefore still influence surgical practice on a 
daily basis. Part of the challenge is that supportive care is the only current treatment for hepatic I/R injury, 
and in that respect, several observations can be made based on the current work. It is the first report that 
shows DAMP release directly after major liver resection, and additionally identifies HMGB1 as the DAMP 
most pertinent to clinical I/R injury. Liver I/R in patients was characterized by an early rise in HMGB1 
levels 1 h after surgery, whereas HMGB1 returned to baseline 6 h after surgery. The early release of 
HMGB1 fits previous reports showing that HMGB1 from hepatocytes is already propagated by ischemia, 
and persists throughout the reperfusion phase in mice subjected to I/R
31
. It is also consistent with the 
finding that HMGB1 is found in the caval effluent immediately after liver transplantation
32
. The notion that 
HMGB1 levels correlated to transaminase release and the duration of ischemia indicates that HMGB1 
may hold prognostic or even therapeutic value, as HMGB1 is an active mediator of immune activation that 
could serve as an interventional target. Small-molecule inhibitors of the HMGB1 receptor RAGE are being 
clinically evaluated for ancillary indications
33
, whereas inhibition of TLR receptors has been proposed to 
treat inflammatory disorders
34
. Direct HMGB1 inhibition has also shown promise in treating drug-induced 
liver injury in mice
35
. This starkly contrasts the liver injury markers such as ALT or bilirubin, which are 
‘passive’ markers for hepatocellular injury that do not modulate immune responses. The latter also 
applies to other hepatic I/R biomarkers such as keratin 18
36
. DAMP-targeted interventions could for 
instance be used on an on-demand basis to control I/R injury in patients with anticipated (or unexpected) 
extensive ischemia times. A similar rationale has driven the introduction of in situ liver cooling 
techniques
37,38
.  
 HMGB1 could theoretically also derive from other cells or organs after liver I/R, such as the 
intestines
39
. It is however most plausible that hepatocytes are the source of HMGB1, for several reasons. 
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First, the postoperative rise in HMGB1 is not seen in hepatocyte-specific HMGB1 knockout mice 
subjected to liver I/R
40
. Similar results have been obtained with mice deficient in hepatocyte TLR-4, an 
innate immune receptor that mediates facilitates HMGB1 release after I/R
24,41
. Second, HMGB1 levels 
were more prominent in caval than in portal blood after liver transplantation
32
, whereas no differences 
were noted between systemic and portal HMGB1 concentrations. The latter excludes the bowel as a 
source of HMGB1 after liver transplantation. Last, in vitro studies have shown that hepatocytes rendered 
hypoxic or exposed to the oxidant hydrogen peroxide release HMGB1 into the culture supernatant
24
. An 
unanswered question is which HMGB1 isoform is released after liver I/R, as the biological effects of 
HMGB1 depend on the oxidation status of the protein
28
. In addition, it should be elucidated how HMGB1 
is inactivated and/or regulated at sites of inflammation. This is imperative given the transient nature of 
postoperative HMGB1 surges noted both after liver transplantation
32
 and in the current study (Fig. 2).  
 The finding that mtDNA levels were unaffected by liver I/R is unexpected, given that mtDNA 
release was seen in mice and patients with acetaminophen (APAP) hepatotoxicity, which 
pathophysiologically resembles I/R in terms of oxidative injury to hepatocyte mitochondria
12,42,43
. The 
discrepancy may relate to several differences between I/R injury and APAP overdose. First, the 
mechanistic pathways culminating in mitochondrial damage are different. In case of APAP, cytoplasmic 
glutathione stores are depleted, leading to the accumulation of the toxic NAPQI that associates with 
mitochondrial proteins and leads to mitochondrial permeability transition (MPT) and necrotic cell death
43
. 
Accordingly, APAP causes cytoplasmic redox stress that subsequently migrates to the mitochondria. In 
case of I/R, the depletion and subsequent repletion of the terminal substrate of the electron transport 
chain (ETC) - molecular oxygen - leads to an oxidative burst and ROS production that perturbs ETC 
proteins by redox modification and causes MPT and mainly necrotic cell death
44
. Mitochondrial damage 
by I/R therefore has a mitochondrial origin, which could translate to differential mtDNA kinetics versus 
APAP-triggered mtDNA kinetics. Corroboratively, mtDNA release seems to be a tightly regulated process 
rather than a mere consequence of necrosis inasmuch as rendering livers necrotic with furosemide 
instead of APAP did not trigger mtDNA release
12
. Second, hepatocellular injury in patients with APAP 
toxicity was considerably more severe than in our I/R cohort based on ALT levels
12
. The proposition that 
mtDNA is released mainly in severe liver injury is also in line with a later report showing that mtDNA 
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release is more pronounced in patients with poor outcome after APAP overdose
11
. One could further 
argue that ischemia by itself is the factor that differentiates APAP toxicity from I/R injury. Indeed, mtDNA 
release has been predominantly reported in patients with non-ischemic causes of sterile injury, which in 
addition tot APAP hepatotoxicity includes inflammatory bowel disease
45
 and trauma patients
46
. This line of 
reasoning, however, does not align with the fact that we also did not find mtDNA release in patients who 
underwent a major hepatectomy without intraoperative VIO use (i.e., non-ischemic sterile liver injury).  
 The current data also highlight that mitochondrial oxidative stress may be an even more proximal 
target for intervention
47
, as this may limit DAMP release. The finding that MitoQ was able to suppress 
HMGB1 release fits the earlier notion that the glutathione precursor n-acetyl-cysteine (NAC) reduced 
HMGB1 release after in vitro hepatocyte anoxia/reoxygenation
24
. Antioxidants, including NAC, lack 
efficacy in various clinical scenarios, including hepatic I/R injury
48
. MitoQ differs from these compounds in 
that it is designed to target the site of oxidant production after I/R (i.e., mitochondria) and also detoxifies 
the most relevant oxidant (i.e., superoxide)
5
. MitoQ has been used previously in mice to successfully treat 
hepatic I/R injury
27
. In the latter report, MitoQ efficacy was assessed using surrogate markers for oxidative 
injury such as mitochondrial protein carbonylation and hepatic 3-nitrotyrosine content
27
. Using a direct 
intravital fluorescence-based method
25
 it was confirmed that MitoQ reduces hepatocyte oxidative stress 
early after I/R. In addition, MitoQ has already been employed in phase II studies where it curtailed 
transaminase levels in patients with hepatitis C
49
, which is an encouraging follow-up to the preclinical 
notion that MitoQ is generally well-tolerated and not toxic
50
. The clinical investigation and implementation 
of mitochondria-targeted antioxidants such as MitoQ therefore seems a realistic objective. 
 Several limitations of the current study should be considered when interpreting the results. The 
observational nature of the current study means that it is neither designed nor powered to detect 
differences in clinical outcomes. The similarity in post-operative liver injury parameters between the I/R 
and control group (Table 2) therefore does not mean that liver ischemia is innocuous, but that VIO in 
experienced hands is a safe salvage procedure when used to counteract the harms of excessive blood 
loss. The relatively favorable post-operative transaminase and bilirubin values recorded in the I/R group 
also relates to the fact that only patients with sufficient (future) remnant liver size and function are eligible 
for major liver resection. This is supported by the fact that the noted extent of liver injury (i.e., ALT 
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release) is comparable to previous clinical liver I/R cohorts
51,52
. The interpretation of the clinical data is 
further hindered by the inability to separate the contribution of ischemic liver injury from the effects of 
surgical trauma on DAMP release. It has for instance been reported that the DAMP ATP is released from 
the resection plane after partial hepatectomy
26
. In the latter study, patients were not exposed to ischemia 
during liver resection. Also, the duration of liver surgery and hepatic manipulation during surgery both 
influence the release of liver injury markers
53
. The longer operating time and trend towards more 
extensive resections in the I/R group (Table 1) may therefore also add to the higher HMGB1 levels in the 
I/R group rather than VIO use only, although this does not per se disqualify the conclusions when 
contextualized to the mouse data. Last, it should be noted that, in line with available evidence
54
, the 
majority of patients were operated using intermittent VIO (Table S4). This technique allows for brief 
periods of parenchymal (re)perfusion in between cycles of liver ischemia. In contrast, most animal models 
of hepatic I/R, including ours, employ continuous liver ischemia. As the anoxic period primes mitochondria 
for the post-ischemic burst of ROS production
6
, it is conceivable that intermittent VIO lessens the extent 
of mitochondrial oxidative injury after I/R. Accordingly, it also means that it remains to be shown whether 
I/R injury resulting from intermittent VIO is amenable to treatment with mitochondria-targeted antioxidants 
such as MitoQ.  
 In conclusion, it is shown that HMGB1 release is related to clinical liver I/R injury. The finding that 
the mitochondria-targeted antioxidant MitoQ limited HMGB1 release and reduced I/R injury in mice may 
pave the way for the clinical use of targeted antioxidants against early-onset radicals and oxidants to 
attenuate hepatic I/R injury.  
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7. Figure legends 
 
 
Figure 1. DAMP release and neutrophil activation after clinical liver I/R 
A-D show plasma levels (median±IQR) of the DAMPs HMGB1, nucleosomes, and mtDNA, and the 
marker for neutrophil activity E-AT at 1 h and 6 h after liver surgery in patients. Note that the y-axes are 
scaled logarithmically. E-AT=elastase-1-antitrypsin complex; HMGB1=high mobility group box 1; 
mtDNA=mitochondrial DNA. # indicates p<0.05 versus t=0.  
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Figure 2. HMGB1 release correlates to postoperative liver injury after major liver resection 
A-D show systemic DAMP levels (median±IQR) for patients operated with VIO (I/R, red) or without VIO 
(control, blue). E-F display the correlation between circulating HMGB1 and liver ischemia time and the 
post-operative hepatocellular injury peak. The dashed lines indicate the 95% confidence interval of the 
regression line. Additional correlation data are presented in Supplemental Figures S3. # indicates p<0.05 
versus t=0 in the I/R group, $ indicates p<0.05 versus t=0 in the control group, and * indicates p<0.05 
between the groups indicated by the solid line. ALT=aspartate alanine aminotransferase; E-AT=elastase-
1-antitrypsin complex; HMGB1=high mobility group box 1; I/R=ischemia/reperfusion; IQR=interquartile 
range; mtDNA=mitochondrial DNA; VIO=vascular inflow occlusion. 
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Figure 3. MitoQ attenuates hepatic I/R injury in mice by suppressing HMGB1 release 
A shows the dose-response relationship between MitoQ and hepatocellular injury. The 1 mg/kg MitoQ 
dosage was used in all subsequent experiments (solid line). B demonstrates that MitoQ mitigated hepatic 
oxidative stress during early reperfusion as measured by real-time in vivo microscopy/spectroscopy. C-D 
show that MitoQ decreased ALT release and hepatocellular necrosis at 24 h reperfusion whereas redox-
inactive MitoQ (dTPP) was not protective (also see Fig. S4). E-F indicate that MitoQ attenuated HMGB1 
release but did not affect intracellular HMGB1 levels. G demonstrates that reconstitution of disulfide 
HMGB1 reverses the protective effects of MitoQ. H-I show that MitoQ decreased expression of the 
leukocyte receptor VCAM-1 but did not affect ICAM-1 expression. The heat map (J) depicts a decrease 
(blue) or increase (red) in plasma cytokine concentration in MitoQ-treated animals subjected to I/R versus 
vehicle-treated animals subjected to I/R. The dots indicate a statistically significant difference between the 
MitoQ and control group. Full hepatocellular damage and cytokine results are included in Supplemental 
Figure S5 and Supplemental Table S6 and a functional description of measured cytokines is included in 
Supplemental Table S3. Results are shown as mean±SEM, except for D (median±range). Western blot 
results are presented as densitometric analysis. One representative blot per group is included per graph. 
Group sizes are ≥6 animals/group, except for B (3-4 mice/group). Area under the curve analysis was 
used to assess differences in ROS production (B). * indicates p<0.05 in the MitoQ versus the I/R group. 
au=arbitrary unit; ALT=aspartate alanine aminotransferase; CDCF=5(6)-carboxy-dichlorofluorescein; 
dTPP= decyl-triphenylphosphonium; ROS=reactive oxygen species; HMGB1=high mobility group box 1; 
ICAM-1=intercellular adhesion molecule 1; VCAM-1=vascular cell adhesion molecule 1. 
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 CTRL (N=13) I/R (N=26) p-value 
Age (years, median ± IQR) 62 (45 – 73) 66 (53 – 70) 0.670 
Gender, male (n, %) 8 (62) 18 (69) 0.725 
BMI (median ± IQR) 25.2 (22.9 – 26.3) 23.9 (20.9 – 26.8) 0.418 
ASA score (n, %) 
 
 
I 
II 
III 
3 (23) 
10 (77) 
0 (0) 
6 (23) 
14 (54) 
6 (23) 
0.153 
Diagnosis (n, %) 
 
 
 
 
 
CRC metastasis 
PHCC 
IHCC 
HCC 
Benign 
Other 
1 (9) 
3 (23) 
2 (15) 
2 (15) 
3 (23) 
2 (15) 
4 (15) 
13 (50) 
2 (8) 
3 (12) 
3 (12) 
1 (3) 
0.132 
Preoperative chemotherapy, yes (n, %) 2 (15) 4 (15) 1.000 
Biliary drainage, yes (n, %) 3 (23) 9 (35) 0.714 
PVE, yes (n, %) 1 (8) 1 (4) 1.000 
ALT baseline, U/L (median ± IQR) 30 (25 – 52) 53 (24 – 71) 0.294 
AST baseline, U/L (median ± IQR) 32 (28 – 52) 45 (28 – 73) 0.178 
Total bilirubin baseline, uM/L (median ± IQR) 9 (6 – 14) 7 (5 – 14) 0.471 
INR baseline (median ± IQR) 1.0 (1.0 – 1.1) 1.0 (1.0 – 1.1) 0.676 
 
Table 1. Baseline characteristics 
Shown are the baseline characteristics of the control (CTRL) and ischemia/reperfusion (I/R) groups.  
ALT=alanine aminotransferase; ASA=American Society of Anesthesiologists; AST=aspartate 
aminostransferase; BMI=body mass index; CRC=colorectal cancer metastases; HCC=hepatocellular 
carcinoma; IHCC=intrahepatic cholangiocarcinoma; INR=international normalized ratio; IQR=interquartile 
range; PHCC=perihilar cholangiocarcinoma; PVE=portal vein embolizationCategorical data were 
analyzed using Fisher’s exact test (binary data) and Chi-square test (>2 variables). Differences between 
numerical variables were assessed using student’s t-tests. 
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 CTRL (N=13) I/R (N=26) p-value 
Resected segments
#
 (%)   0.131 
 3 6 (46.2%) 5 (19.2%)  
 ≥4 7 (53.8%) 21 (80.8%)  
Resection time, min (medianIQR) 59 (41.5 – 71.5) 82 (60 – 130) 0.006 
Duration of ischemia
&
 min (medianIQR) N/A 48 (31 – 68)  
Duration of surgery, min (medianIQR) 306 (261 – 373.5) 460 (380 – 503) 0.001 
Transfusion requirement, units (%)   0.455 
 0 9 (62.9) 12 (48)  
 1-2 2 (15.4) 6 (24)  
 ≥3 2 (15.4) 7 (28)  
Hospital stay, days (medianIQR) 9 (7.5 – 11) 11.5 (8 – 22) 0.036 
Grade III-V complications
@
 (%) 7 (53.8) 13 (52) 1.000 
ICU admission (%) 3 (23.1) 7 (26.9) 1.000 
In-hospital mortality (%) 1 (7.7)  2 (8.0) 1.000 
Peak ALT, U/L (medianIQR) 273 (142.5 – 641.5) 456 (289 – 784) 0.152 
Peak INR (medianIQR) 1.19 (1.12 – 1.31) 1.30 (1.17 – 1.41) 0.411 
Peak total bilirubin, mol/L (medianIQR) 17 (14 – 34) 32 (19 –47) 0.129 
 
 
Table 2. Clinical outcomes. 
# Designates the number of resected Couinaud liver segments. & Patients were subjected to continuous 
or intermittent vascular inflow occlusion as specified in Supplemental Table S4. Details on the resected 
liver segments can be found in Supplemental Tables S4 and S5.  @ Complications were scored 
according to the Clavien-Dindo classification 
14
. A histopathological assessment of the resection 
specimens is included in Supplemental Table S4. CTRL=control group; I/R=ischemia/reperfusion group; 
ALT=aspartate alanine aminotransferase; ICU=intensive care unit; INR=international normalized ratio; 
IQR=interquartile range; min=minutes. Categorical data were analyzed using Fisher’s exact test (binary 
data) and Chi-square test (>2 variables). Differences between numerical variables were assessed using 
student’s t-tests. 
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Abstract  
Objective and background. Activation of sterile inflammation after hepatic I/R culminates in liver injury. 
The route to liver damage starts with mitochondrial oxidative stress and cell death during early 
reperfusion. The link between mitochondrial oxidative stress, damage-associate molecular pattern 
(DAMP) release, and sterile immune signalling is incompletely understood and lacks clinical validation. 
The aim of the study was to investigatevalidate this relation in a clinical liver I/R cohort and to limit DAMP 
release using a mitochondria-targeted antioxidant in I/R-subjected mice. 
Methods. Plasma levels of the DAMPs high-mobility group box 1 (HMGB1), mitochondrial DNA, and 
nucleosomes were measured in 39 patients enrolled in an observational study who underwent a major 
liver resection with (N=29) or without (N=13) intraoperative liver ischemia. Circulating cytokine and 
neutrophil activation markers were also determined. In mice, the mitochondria-targeted antioxidant MitoQ 
was intravenously infused in attempt to limit DAMP release, reduce sterile inflammation, and suppress I/R 
injury. 
Results. In patients, HMGB1 was elevated following liver resection with I/R compared to liver resection 
without I/R. HMGB1 correlated positively with ischemia duration and peak post-operative transaminase 
(ALT) levels. There were no differences in mitochondrial DNA, nucleosome, or cytokine release. In mice, 
MitoQ neutralized hepatic oxidative stress and decreased HMGB1 release by ±50%. MitoQ suppressed 
transaminase release, hepatocellular necrosis, and cytokine production. Reconstituting disulfide HMGB1 
during reperfusion reversed these protective effects. 
Conclusion. HMGB1 seems the most pertinent DAMP toin clinical hepatic I/R injury. Neutralizing 
mitochondrial oxidative stress may limit DAMP release after hepatic I/R and reduce liver damage. 
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Abbreviations: 
ALT = alanine aminotransferase 
ASA = American Society of Anesthesiologists 
AST = aspartate aminotransferase 
BMI = body mass index 
CTRL = control (group) 
CRC = colorectal cancer metastasis 
DAMP = damage-associated molecular pattern 
dTPP = decyl-triphenylphosphonium  
HCC = hepatocellular carcinoma 
HMGB1 = high-mobility group box 1 
I/R = ischemia/reperfusion 
ICAM = intercellular adhesion molecule  
IHC = intrahepatic cholangiocarcinoma 
IL = interleukin 
INR = international normalized ratio 
IQR = interquartile range 
mtDNA = mitochondrial DNA 
PHCC = perihilar cholangiocarcinoma 
PVE = portal vein embolization 
RAGE = receptor for advanced glycation end products 
ROS = reactive oxygen species 
TLR = toll-like receptor 
NAC = N-acetylcysteine 
VIO = vascular inflow occlusion 
VCAM = vascular cell adhesion protein  
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1. Introduction 
During major liver resection, the induction of liver ischemia by surgical clamping of the afferent hepatic 
vasculature is used to counter the risks of excessive blood loss. This surgical technique is known as 
vascular inflow occlusion (VIO) or the Pringle maneuver
1
. When employed within predefined time limits 
and in selected patients, this manoeuvre is considered safe. TheHowever, the transient lack of organ 
perfusion and oxygenation however also inadvertently causes ischemia/reperfusion (I/R) injury
2-4
 and the 
severity of hepatic I/R injury impacts the recovery of patients after major liver surgery.  
 Activation of sterile inflammation is a key feature of hepatic I/R injury. During ischemia, the lack of 
oxygen halts oxidative phosphorylation and leads to the build-up of citric acid cycle metabolites such as 
succinate
5,6
. Once the oxygen supply is restored, the consumption of accumulated succinate during the 
first minutes of reperfusion fuels a burst of reactive oxygen species (ROS) production by the 
mitochondrial electron transport chain
5,6
. The consequent wave of ROS-induced cell death triggers the 
release of damage-associated molecular patterns (DAMPs) by hepatocytes. DAMPs are innocuous 
intracellular constituents that become potent triggers of the innate immune system once released into the 
circulation
2,7
. Effector cells of the innate immune system such as neutrophils in turn confer the bulk of 
hepatic tissue injury. Based on this sequence of events, DAMPs occupy a crucial role in the onset of I/R 
injury as signal transducers and amplifiers of the sterile immune response. 
 Several DAMPs, including histones
8
, DNA
9
, and high-mobility group box 1 (HMGB1)
10
 have been 
causally linked to hepatic I/R injury in animal studies. DAMP release has also been measured in clinical 
accounts of sterile liver injury
11,12
. However, the link between mitochondrial oxidative stress and DAMP 
release has not been clinically elaborated in the context of hepatic I/R injury to date, and was therefore 
investigated in this study. To that end, DAMP release was studied in patients undergoing liver resection 
with or without being subjected to I/R.   
 It is shown that patients who underwent major liver surgery rapidly exhibit DAMP release after 
resection. Of the tested DAMPs, only HMGB1 levels increased specifically in I/R-subjected patients and 
not in the control group operated without I/R. HMGB1 release correlated positively with ischemia time and 
postoperative hepatocellular injury markers. The results were back-translated to a validated mouse 
model
13
 to allow experimental confirmation and further elaboration. Decreasing mitochondrial oxidative 
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damage during early reperfusion with the mitochondria-targeted antioxidant MitoQ in mice prevented 
HMGB1 release and attenuated the I/R immune response. Decreasing mitochondrial oxidative damage 
therefore may potentially improve outcomes in patients undergoing major liver surgery. 
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2. Materials and methods 
 
 
References to the supplemental information are indicated with the prefix ‘S’.  
 
2.1 Study participants and study design 
The effect of liver surgery performed with or without intraoperative liver ischemia on DAMP release was 
investigated in a single-centrecenter observational trial registered at https://ClinicalTrials.gov under 
identifier NCT01700660. Eligible for participation were all patients scheduled for a major liver resection 
(removal of ≥3 Couinaud segments) that were ≥18 years old and had an American Society of 
AnaesthesiologyAnesthesiology physical status score of 3. Patients were excluded from the study when 
considered unresectable during surgical exploration, when the employed ischemia time was <20 min, 
when they underwent an emergency operation, or when the patient was pregnant or breast-feeding. 
Because the decision whether or not to use vascular inflow occlusion (VIO) and thereby subject patients 
to I/R was made at the discretion of the performing surgeon based on the actual or anticipated amount of 
blood loss, participants were non-randomly assigned to either the I/R group (N=26) or the control group 
(N=13). Intermittent VIO was typically performed in cycles comprising 20 min of ischemia followed by 10 
min of reperfusion. In a minor fraction of patients, the operative cause necessitated the use of continuous 
VIO (see Supplemental Table S4).  All patients were operated by the same primary surgeon (TvGTVG).  
 Blood samples were drawn from a central venous catheter after the induction of general 
anaesthesiaanesthesia (i.e., at baseline) and 1 and 6 h after the start of reperfusion (I/R group) or 
completion of parenchymal transection (CTRL group). Plasma liver injury (ALT) and liver function 
(international normalized ratio (INR), total bilirubin) were determined as part of routine patient care. Post-
operative complications were categorized according to the Clavien-Dindo grading system
13
system
14
. All 
experimental results were normalized to plasma protein content (Pierce BCA Protein Assay Kit, Life 
Technologies, Carlsbad, CA) to correct for hemodilution, as described
14
described
15
. All study protocols 
ware approved by the Institutional Review Board and written informed consent was obtained from all 
participants before undergoing any study-related procedures. The study design is summarized in 
Supplemental Figure S1. 
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2.2 Circulating HMGB1  
Plasma HMGB1 levels were determined in 10 L of EDTA-anticoagulated plasma samples by ELISA (IBL 
International, Hamburg, Germany) according to manufacturer’s instructions. All samples were measured 
in duplicate in regular sensitivity mode on a Synergy HT microplate reader (BioTek Instruments, 
Winooski, VT). 
 
2.3 Circulating nucleosomes and elastase-1-antitrypsin complexes 
Nucleosome levels were assessed by ELISA as previously described
15
described
16
. Briefly, monoclonal 
antibody CLB-ANA/60 (Sanquin, Amsterdam, the Netherlands) that recognizes histone 3 was used as 
capture antibody. Biotinylated F(ab)2 fragments of monoclonal antibody CLB-ANA/58 (Sanquin), which 
recognizes an epitope exposed on complexes of dsDNA histone 2A and histone 2B in combination with 
poly-horseradish peroxidase–labelledlabeled streptavidin (Sanquin) were used for detection. As a 
standard, we used culture supernatant of Jurkat cells (1×10
6
 cells/mL), cultured for an additional week 
without refreshing the medium, to obtain 100% apoptotic cells. One unit is the amount of nucleosomes 
released by ≈100 Jurkat cells. The lower detection limit of the assay was 2.5 U/mL
16
mL
17
. The reference 
range for circulating nucleosomes in healthy individuals is 0-10.3 U/mL. 
 Elastase-1-antitrypsin complexes (E-AT) were measured by ELISA as described
17
described
18
. 
This assay was adapted from a previously described radioimmunoassay
18
radioimmunoassay
19
. Briefly, 
plates were coated with a polyclonal rabbit anti-human neutrophil elastase antibody (1.5 μg/mL; Sanquin). 
Standard and samples were diluted in high-performance ELISA buffer (HPE; Sanquin) + 40 μg/mL bovine 
IgG. Bound complexes were detected with a biotinylated monoclonal anti–α1 -antitrypsin antibody (1 
μg/mL; Sanquin) in combination with poly-horseradish peroxidase–labelledlabeled streptavidin. Results 
are expressed in ng/mL by reference to a standard curve of normal human citrated plasma in which EA-T 
were generated by incubation with porcine elastase (final concentration 2 μg/mL; Sigma, Zwijndrecht, the 
Netherlands) for 15 min at room temperature. The detection limit of the assay was 2 ng/mL. The 
reference range for EA-T in healthy individuals is 8.5 to 55.7 ng/mL. 
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2.4 Circulating mitochondrial DNA   
Plasma mitochondrial DNA levels were determined according to Nakahira et al.
1920
, with minor 
modifications. Total DNA was isolated from 190 μL of heparin-anticoagulated plasma using the QIAamp 
DNA Blood Mini Kit (cat. #51106, Qiagen) according to the manufacturer’s instructions. DNA was eluted 
in 100 μL of elution buffer. Levels of mitochondrial DNA (mtDNA) were analyzed in duplicate by real-time 
quantitative PCR on a Lightcycler 480 (Roche) using a reaction volume of 10 L consisting of 2 L of 
DNA, 2 L of nuclease-free water (Qiagen), 1 L of primer mix (0.5 M final primer concentration), and 5 
L of SensiFAST SYBR No-ROX mix (Bioline, London, UK). The run parameters are specified in 
Supplemental Table S1. The following primers were used: human mitochondrially-encoded NADH 
dehydrogenase 1 (MT-ND1): forward 5’-ATACCCATGGCCAACCTCCT-3’, reverse 5’-
GGGCCTTTGCGTAGTTGTAT-3’
12
. Melting curve analysis and ethidium bromide-stained agarose gel 
electrophoresis were used to validate primer specificity. A plasmid encoding a human cDNA clone of MT-
ND1 was purchased from ORIGENE (SC101172) and was used as a logarithmic mtDNA standard in 10-
fold serial dilutions (1.93 x 10
6
 copies – 1.93 x 10
0
 copies). Data waswere processed according to Ruijter 
et al.
2021
, fitted to the mtDNA standard, and normalized to plasma protein content. 
 
2.5 Human plasma cytokine measurements 
L-12p70, TNF, IL-10, IL-6, IL-1, and IL-8/CXCL8 concentrations were determined in serum samples 
using the Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit (BD Biosciences, Franklin, 
NJ) according to the manufacturer's instructions. The samples were analyzed in a blinded fashion and 
flow data were collected using a BD FACSCanto II (BD Biosciences). The results were analyzed with 
FCAP Array version 3.0 software (BD Biosciences). CCL2 plasma concentration was measured by ELISA 
(Duosets, R&D Systems, Minneapolis, MN). All reagents and solutions were prepared fresh each week 
according to the manufacturer’s protocols and were sterile filtered using 0.2 μM bottle-top vacuum filters 
(Corning, Corning, NY). Bovine serum albumin was of the highest available purity (cat. #A7030, Sigma-
Aldrich, St. Louis, MO) and ELISAs were performed using clear 96-well flat bottom polystyrene 
microplates (#9018, Corning). All cytokine levels were normalized to plasma total protein content.  
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2.6 Mouse hepatic ischemia/reperfusion experiments 
The animal experiments were approved by the institute’s animal welfare committee and surgical 
procedures were as described
21
described
13
. MitoQ was dissolved to a concentration of 6 mg/mL MitoQ in 
sterile NaCl (Braun). After induction of anesthesia, 250 ng/kg – 3 mg/kg MitoQ or an equimolar amount of 
the inactive targeting moiety decyl-triphenylphosphonium (dTPP) in sterile NaCl was infused via the 
penile vein in a volume of 100 L per 30 g body weight. After allowing MitoQ or dTPP to circulate for 10 
min, partial (70%) liver ischemia was induced for 30 min
21
min
13
. As a control group, animals underwent 
sham surgery that entailed a laparotomy with mobilization of hilar structures, but without actual occlusion 
of the afferent vasculature. For every set of experiments, animals were randomly assigned to an 
experimental arm. For HMGB1 reconstitution experiments, 2.5 g disulfide HMGB1 (IBL) in 100 L sterile 
NaCl was administered intraperitoneally immediately after reperfusion was initiated. Disulfide HMGB1 
was selected for the reconstitution experiments because (1) it is the predominant isoform released in 
mice subjected to hemorrhagic shock and resuscitation
22
 - a model that pathophysiologically resembles 
liver I/R - and (2) the disulfide isoform activates the hepatic I/R-pertinent TLR-4 signaling axis
10,23,24
. 
Animals were sacrificed at 6 h or 24 h of reperfusion. Blood and liver samples were processed as 
described
21
. To account for slightdescribed
13
. The number of animals per group per experiment is 
included in the figure legends. To account for variations in experimental conditions and animal batches, a 
new control group of vehicle-treated mice subjected to I/R was included in every new set of experiments. 
Clinical chemistry results of the mouse experiments are therefore expressed as a percentage of this 
reference group.  
 
2.7 Mouse liver histology  
Mouse liver specimens were fixed in formalin, embedded in paraffin, and stained with hematoxylin and 
eosin as described
21
described
13
. The extent of confluent parenchymal necrosis was scored by a 
hepatopatoholigst (JV) according to the following grading system: 0=no necrosis, 1=<25% necrosis, 
2=25-50% necrosis, 3=50-75% necrosis, and 4=>75% necrosis. 
 
2.8 Western blot  
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Frozen liver (-80 
o
C) samples were homogenized with an Omni Tissue Master 125 (Omni International, 
Kennesaw, GA) in cell lysis buffer (50 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% 
glycerol, 0.1% tritonTriton X-100 containing protease and phosphatase inhibitors). Cell debris was 
pelleted (12,000 x g, 5 min), supernatant protein content determined (DC Protein Assay, Bio-Rad), and 
SDS-polyacrylamide gel electrophoresis (Bio-Rad Mini-PROTEAN) was performed with samples 
standardized to 30 µg protein/well. Proteins were separated using 7.5% gels, followed by electrophoretic 
elution onto PVDF membranes (Trans-Blot Turbo, Bio-Rad), as per manufacturer’s instructions. Blots 
were run under reducing conditions. PVDF membranes were blocked (5% skim- milk, 1 h), incubated with 
primary antibodies (Supplemental Table S1) for 16 h (4 
o
C) and stained with appropriate HRP-conjugated 
secondary antibodies (Santa Cruz). Immunoreactivity was detected using SuperSignal West Femto 
Substrate (Thermo Scientific) and digital chemiluminescence image capture (LAS-4000, FujiFilm, Tokyo, 
Japan). Densitometry was quantified usingDensitometric analysis was performed with MultiGauge 
software (V3.0, FujiFilm, Tokyo, Japan), and all values were normalized to the expression of the 
housekeeping protein -actin. All experiments were performed in triplicate. 
 
2.9 Mouse plasma cytokine measurements 
Mouse plasma samples were assayed for mouse GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL12p70, IL-
13, IL-18, and TNF- using the ProcartaPlex Mouse Th1/Th2 extended 11-plex kit and mouse BAFF, IL-
10, IL-22, RANTES/CCL5, TSLP, and VEGF-A using ProcartaPlex simplex kits on the Luminex platform 
(Affymetrix, Santa Clara, CA), according to the manufacturer’s instructions. The relevance of these 
inflammatory messengers for hepatic I/R injury is summarized in Supplemental Table S3. In brief, 
samples were thawed on ice. The antibody-coated beads were mixed and washed, and subsequently 
incubated overnight at 4 °C with 1:1 diluted standards or samples. After washing, the beads were 
incubated with detection antibody mix for 30 min at room temperature. The beads were subsequently 
washed and incubated for 30 min at room temperature with streptavidin-PE. After washing, the beads 
were measured with a Luminex instrument (Bio-Plex 200, Bio-Rad) that was calibrated using Bio-Rad 
calibration beads. Standard curves were calculated using 5-parameter logistic regression in Bioplex 5.0 
software. Heatmaps were generated using GENE-E software 
  - 12 - 
(http://www.broadinstitute.org/cancer/software/GENE-E/) and show the plasma cytokine levels of MitoQ-
treated mice following 30 min of ischemia and 6 h or 24 h of reperfusion. Data per time point are 
expressed as fold-increase compared to the mean of the vehicle control group, whereby blue indicates a 
decrease and red indicates an increase in the MitoQ group versus control animals subjected to I/R only.  
 
2.10 Intravital imaging and spectroscopic quantification of reactive oxygen species production during 
hepatic I/R injury in mice 
The oxidation-sensitive fluorogenic probe 5(6)-carboxy-dichlorodihydrofluorescein was prepared from 
5(6)-carboxy-dichlorodihydrofluorescein diacetate and encapsulated in hepatocyte-targeted liposomes 
according to Reiniers et al
25
. Liposomes (0.1 mol lipid/g body weight in 200 L 10 mM HEPES, 0.88% 
NaCl, 0.292 osmol/kg, pH = 7.4) were injected via the penile vein and circulated for 35 min to allow 
intrahepatic accumulation. Hepatic I/R was subsequently performed as described
25
. To perform the 
surgical procedure with the mice positioned under the intravital imaging setup, ischemia was induced with 
a silicone sling placed around the hepatic pedicle instead of a microvascular clamp. During the first 10 
min of reperfusion, hepatic probe conversion was quantified at 2-min intervals in real-time using a 
customized intravital fluorescence microscope (M165FC, Leica Microsystems, Wetzlar, Germany) 
equipped with a spectrometer (QE65000, Ocean Optics, Dunedin, FL). Spectroscopic data were 
integrated over the entire spectral width ( = 250–1050 nm) and normalized to baseline.  
 
2.11 Statistical analyses 
Statistical analyses were performed using Graphpad Prism 6 (La Jolla, CA) and SPSS 21.0 (Chicago, IL), 
abiding by a significance level (α) of 0.05 unless otherwise indicated. Normal distribution of data sets with 
8 values was assessed using a D’Agostino and Pearson omnibus test. Normally distributed data were 
tested for intragroup and intergroup differences using a student’s t-test, a one-way ANOVA with Dunnet’s 
post-hoc test, or a repeated measure ANOVA with Geisser-Greenhouse correction and Tukey’s post-hoc 
correction. All continuous numerical variables that failed the normality test were log transformed and re-
analyzed. Log-transformed data that followed a Gaussian distribution were analyzed parametrically as 
described. If the transformed data failed the normality test, non-parametric tests (Mann Whitney U, 
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Kruskall-Wallis with Dunn’s post-hoc test, or Friedman with Dunn’s correction) were performed on the 
non-transformed data. Data sets with <8 values group were tested parametrically. Categorical data were 
analyzed using a Fisher’s exact test (binary data) or a Chi-squared test (>2 variables) and correlations 
were tested using Spearman’s rho.   Formatted: English (United
States)
  - 14 - 
3. Results 
 
3.1 DAMP release after major liver resection in patients 
To study DAMP release after clinical liver I/R, a total of 74 patients were enrolled in an observational 
study. Of the 74 study participants, 35 were excluded due to unresectable disease during surgical 
exploration (N=30), withdrawal of consent (N=1), an unanticipated change in primary surgeon (N=1), or 
because a minor instead of a major liver resection was performed (N=3). The relationship between 
hepatic I/R injury and DAMP release was therefore studied in 39 patients who underwent a major liver 
resection with (N=26, ‘I/R’) or without (N=13, ‘CTRL’) the intraoperative use of VIO. The study design is 
summarized in Supplemental Figure S1. The baseline patient characteristics are shown in Table 1 and 
the clinical outcomes are presented in Table 2. 
 The baseline patient characteristics were comparable between the two study arms. VIO use was 
associated with longer operating time, resection time, and hospital stay compared to the control group 
(Table 2). A trend towards more extensive liver resection was seen in the I/R group (Table 2). The 
severity of postoperative liver injury did not differ between the groups when judged by liver damage (i.e. 
the postoperative ALT peak) or liver function parameters such as INR orand bilirubin (Table 2). There 
were also no differences in transfusion requirements, postoperative complications, or mortality between 
the control and I/R group (Table 2). As the aim of the study was to explore DAMP release and activation 
of sterile inflammation in I/R-subjected patients, it should be underscored that the study was neither 
designed nor powered to detect differences in patient outcomes between the control and I/R group.  
 Systemic DAMP levels were next determined in the full cohort at baseline and at 1 h and 6 h after 
surgery. HMGB1 and nucleosomes were assessed based on preclinical hepatic I/R work
8,24
. Circulating 
mitochondrial DNA (mtDNA) was assayed because hepatic I/R injury is thought to originate in ROS-
generating mitochondria
5
 and because mtDNA release has been documented in both animal and clinical 
studies on sterile liver injury
11,12
. Figure 1A-B show that systemic HMGB1 and nucleosomes 
concentrations increased within 1 h after surgery in the combined cohort, which was accompanied by a 
rise in neutrophil activation (Fig. 1D). Systemic mtDNA levels remained unchanged during the first 6 h of 
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reperfusion (Fig. 1C). These data show that the DAMPs HMGB1 and nucleosomes are released into the 
circulation after major liver resection.  
To determine whether DAMP release was caused by ischemia-mediated hepatocyte injury or by 
surgical trauma per se, which has been noted previously
26
, the patient data were next stratified into an I/R 
and a control group. Figure 2A-D show that, of the tested DAMPs, only HMGB1 levels increased 
significantly at 1 h of reperfusion in the I/R group but not in the control group. The release of the cytokines 
interleukin (IL)-1 and IL-6 was also more pronounced in the I/R group than in the control group at 1 h of 
reperfusion (Fig. S2). The early intergroup differences in HMGB1 and cytokine release resolved 6 h after 
surgery (Fig. 2A, S2). Nucleosome release and neutrophil activation were comparable between groups at 
all time points (Fig. 2B-C).  In line with the release of HMGB1 in only the I/R group, systemic HMGB1 
levels after surgery correlated positively to the postoperative ALT peak (Fig. 2E) and the used duration of 
hepatic ischemia (Fig. 2F). Such a relationship was typically absent for cytokine levels or neutrophil 
activation (Fig. S3). Collectively, these results suggest that HMGB1 is the DAMP that is most pertinent to 
clinical hepatic I/R injury.  
 
3.2 Neutralizing mitochondrial oxidative stress limits HMGB1 release after mouse liver I/R 
After establishing that HMGB1 is released in patients after hepatic I/R, the therapeutic efficacy of 
inhibiting HMGB1 release was investigated in a validated mouse hepatic I/R model
21
model
13
.  
Because mitochondrial oxidative injury is considered the most proximal trigger of I/R injury and therefore 
may cause the release of DAMPs, it was tested whether the mitochondria-targeted antioxidant MitoQ 
could limit HMGB1 release and, thereby, attenuate hepatic I/R injury in mice. The cytoprotective efficacy 
of MitoQ was established first. The intravenous administration of MitoQ reduced plasma ALT levels at 6 h 
and 24 h of reperfusion in mice over a 0.25-1 mg/kg dose range (Fig. 3A), whereas non-specific MitoQ 
toxicity was seen at higher dosages. Based on this pharmacodynamic profile, 1 mg/kg of MitoQ was used 
in all in vivo experiments.  
 In concordance with a previous report demonstrating the antioxidant efficacy of MitoQ in I/R-
subjected mice
27
, MitoQ reduced oxidation of the fluorogenic probe 5(6)-carboxy-dichlorofluorescein in 
hepatocytes during the first 10 min of reperfusion, as measured by intravital spectroscopy (Fig. 3B). The 
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fluorogenic probe was delivered specifically to hepatocytes using a hepatotargeted delivery system
25
. 
MitoQ did not affect the number of leukocytes in the hepatic microcirculation during the first 90 min of 
reperfusion (Fig. S8, S9S6, S7). The early reduction in oxidative stress (Fig. 3B) however did 
translatetranslated to a drop in hepatocellular necrosis and transaminase release at 24 h of reperfusion 
(Fig. 3C-D), indicating a reduction in hepatic I/R injury. Animals that received the inactive targeting moiety 
of MitoQ, dTPP, were not protected from I/R injury (Fig. 3C-D), reaffirming that the antioxidant properties 
of the ubiquinol moiety convey the hepatoprotective effects of MitoQ. 
 After demonstrating that MitoQ was able to reduce I/R injury, the effect of neutralizing 
mitochondrial oxidative stress on HMGB1 release after mouse liver I/R was explored next. Figure 3E 
shows that MitoQ reduced plasma HMGB1 levels after I/R by approximately 50% at 6 h of reperfusion. 
Quantification of HMGB1 in liver biopsies by Western blot showed similar HMGB1 levels in MitoQ-treated 
and untreated mice subjected to I/R (Fig. 3F). This finding may relate to differences in resolving capacity 
between the techniques used for plasma and whole-liver HMGB1 quantification. To examine whether 
HMGB1 release was associated with the documented hepatoprotective effect of MitoQ, DAMP 
reconstitution experiments were performed next. Infusing the pro-inflammatory disulfide isoform of 
HMGB1
28
 at the start of reperfusion nullified the protective potential of MitoQ (Fig. 3G), which supports 
the hypothesis that I/R injury sequentially proceeds via mitochondrial oxidative injury and DAMP release.  
 Systemic HMGB1 alerts the immune system via the receptor for glycation end products (RAGE) 
and/or Toll-like receptor 4 (TLR-4)
24,29
, which drive cytokine production by activating various pro-
inflammatory transcription factors. After establishing that neutralizing mitochondrial oxidative stress with 
MitoQ decreased HMGB1 release and reduced hepatic I/R injury, it was next investigateddetermined 
whether MitoQ treatment also attenuated inflammatory signallingsignaling following mouse liver I/R. 
Levels of chemotactic and cytotoxic messengers such as tumourtumor necrosis factor (TNF-) and 
interleukin (IL-)1 were lower in the MitoQ group at 6 h of reperfusion, whereas a stronger induction of 
anti-inflammatory IL-10 was noted at the 24 h time point (Fig. 3J). This favourablefavorable effect of 
MitoQ on cytokine profiles may have resulted in the downregulation of the leukocyte receptor VCAM-1, 
even though the expression of the principal sinusoidal neutrophil receptor ICAM-1 was unaffected (Fig. 
3HI).  
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4. Discussion  
This study shows that (i) the DAMP HMGB1 seems most pertinent toin clinical liver I/R injury, (ii) that 
HMGB1 levels positively correlate with liveliver injury markers in I/R-subjected patients, and (iii) that 
treating mitochondrial oxidative injury with MitoQ prevents HMGB1 release and consequent sterile 
inflammation, ultimately attenuating I/R injury in mice.  
 Hepatic I/R injury remains a clinical challenge. Although a downward trend in VIO use has been 
reported
30
, this may relate to the advent of laparoscopic liver surgery, the tendency to undertake 
parenchyma sparing resections, and demographic differences between regions. Even if routine VIO use 
were on the decline, it can be necessary to curtail excessive blood loss during complex resections. 
Moreover, patients can be excluded from surgery based on the preoperative assessment of future 
remnant liver volume and function, a decision that also considers potential effects of I/R on the liver 
remnant. Nevertheless, major Major liver resection remains associated with considerable mortality, 
exceeding 10% in patients with high-risk tumors
31
. These data indicate that thetumors
30
. The ramifications 
of liver ischemia therefore still influence surgical practice on a daily basis.  
 Part of the challenge is that supportive care is the only current treatment for hepatic I/R injury, 
and in that respect, several observations can be made based on the current work. It is the first report that 
shows DAMP release directly after major liver resection, and additionally identifies HMGB1 as the DAMP 
most pertinent to clinical I/R injury. The finding that mtDNA levels were unaffected by liver I/R is 
surprising, given that mtDNA release was seen in patients with acetaminophen intoxication, which 
pathophysiologically resembles I/R in terms of oxidative liver injury
12
. It should be noted, however, that 
the primary site of oxidative stress differs between hepatic I/R injury (mitochondria) and acetaminophen 
overdose (cytosol). How the subcellular site of (initial) hepatocyte injury affects the release of specific 
DAMPs remains to be experimentally pursued.  
 Liver I/R in patients was characterized by an early rise in HMGB1 levels 1 h after surgery, 
whereas HMGB1 returned to baseline 6 h after surgery. The early release of HMGB1 fits previous reports 
showing that HMGB1 from hepatocytes is already propagated by ischemia, and persists throughout the 
reperfusion phase in mice subjected to I/R
31
. It is also consistent with the finding that HMGB1 is found in 
the caval effluent immediately after liver transplantation
32
. The notion that HMGB1 levels correlated to 
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transaminase release and the duration of ischemia indicates that HMGB1 may hold prognostic or even 
therapeutic value, as HMGB1 is an active mediator of immune activation that could serve as an 
interventional target. Small-molecule inhibitors of the HMGB1 receptor RAGE are being clinically 
evaluated for ancillary indications
32
indications
33
, whereas inhibition of TLR receptors has been proposed 
to treat inflammatory disorders
33
disorders
34
. Direct HMGB1 inhibition has also shown promise in treating 
drug-induced liver injury in mice
34
mice
35
. This starkly contrasts the liver injury markers such as ALT or 
bilirubin, which are ‘passive’ markers for hepatocellular injury that do not modulate immune responses. 
The latter also applies to other hepatic I/R biomarkers such as keratin 18
35
18
36
. DAMP-targeted 
interventions could for instance be used on an on-demand basis to control I/R injury in patients with 
anticipated (or unexpected) extensive ischemia times. A similar rationale has driven the introduction of in 
situ liver cooling techniques
36,37
techniques
37,38
.  
 Although HMGB1 after liver I/R could theoretically also derive from other cells or organs after liver 
I/R, such as the intestines
38
, literature suggestsintestines
39
. It is however most plausible that hepatocytes 
are the source of HMGB1, for several reasons. First, the postoperative rise in HMGB1 is not seen in 
hepatocyte-specific HMGB1 knockout mice subjected to liver I/R
39
R
40
. Similar results have been obtained 
with mice deficient in hepatocyte TLR-4, an innate immune receptor that mediates facilitates HMGB1 
release after I/R
24,4041
. Second, HMGB1 levels were more prominent in caval than in portal blood after 
liver transplantation
41
transplantation
32
, whereas no differences were noted between systemic and portal 
HMGB1 concentrations. The latter excludes the bowel as a source of HMGB1 after liver transplantation. 
Last, in vitro studies have shown that hepatocytes rendered hypoxic or exposed to the oxidant hydrogen 
peroxide release HMGB1 into the culture supernatant
24
. CurrentAn unanswered questions arequestion is 
which HMGB1 isoform is released after liver I/R, as the biological effects of HMGB1 depend on the 
oxidation status of the protein
28
. In addition, it should be elucidated how HMGB1 levels areis inactivated 
and/or regulated at sites of inflammation. This is imperative given the transient nature of postoperative 
HMGB1 surges noted both after liver transplantation
41
transplantation
32
 and in the current study (Fig. 2).  
 The presented data also highlight that detoxifying mitochondrial oxidative stress may be an even 
more proximal target for intervention The finding that mtDNA levels were unaffected by liver I/R is 
unexpected, given that mtDNA release was seen in mice and patients with acetaminophen (APAP) 
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hepatotoxicity, which pathophysiologically resembles I/R in terms of oxidative injury to hepatocyte 
mitochondria
12,42,43
. The discrepancy may relate to several differences between I/R injury and APAP 
overdose. First, the mechanistic pathways culminating in mitochondrial damage are different. In case of 
APAP, cytoplasmic glutathione stores are depleted, leading to the accumulation of the toxic NAPQI that 
associates with mitochondrial proteins and leads to mitochondrial permeability transition (MPT) and 
necrotic cell death
43
. Accordingly, APAP causes cytoplasmic redox stress that subsequently migrates to 
the mitochondria. In case of I/R, the depletion and subsequent repletion of the terminal substrate of the 
electron transport chain (ETC) - molecular oxygen - leads to an oxidative burst and ROS production that 
perturbs ETC proteins by redox modification and causes MPT and mainly necrotic cell death
44
. 
Mitochondrial damage by I/R therefore has a mitochondrial origin, which could translate to differential 
mtDNA kinetics versus APAP-triggered mtDNA kinetics. Corroboratively, mtDNA release seems to be a 
tightly regulated process rather than a mere consequence of necrosis inasmuch as rendering livers 
necrotic with furosemide instead of APAP did not trigger mtDNA release
12
. Second, hepatocellular injury 
in patients with APAP toxicity was considerably more severe than in our I/R cohort based on ALT levels
12
. 
The proposition that mtDNA is released mainly in severe liver injury is also in line with a later report 
showing that mtDNA release is more pronounced in patients with poor outcome after APAP overdose
11
. 
One could further argue that ischemia by itself is the factor that differentiates APAP toxicity from I/R 
injury. Indeed, mtDNA release has been predominantly reported in patients with non-ischemic causes of 
sterile injury, which in addition tot APAP hepatotoxicity includes inflammatory bowel disease
45
 and trauma 
patients
46
. This line of reasoning, however, does not align with the fact that we also did not find mtDNA 
release in patients who underwent a major hepatectomy without intraoperative VIO use (i.e., non-
ischemic sterile liver injury).  
 The current data also highlight that mitochondrial oxidative stress may be an even more proximal 
target for intervention
47
, as this may limit DAMP release. The finding that MitoQ was able to suppress 
HMGB1 release fits the earlier notion that the glutathione precursor n-acetyl-cysteine (NAC) reduced 
HMGB1 release after in vitro hepatocyte anoxia/reoxygenation
24
. Antioxidants, including NAC, lack 
efficacy in various clinical scenarios, including hepatic I/R
42
R injury
48
. MitoQ differs from these 
compounds in that it is designed to target the site of oxidant production after I/R (i.e., mitochondria) and 
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also detoxifies the most relevant oxidant (i.e., superoxide)
5
. MoreoverMitoQ has been used previously in 
mice to successfully treat hepatic I/R injury
27
. In the latter report, MitoQ efficacy was assessed using 
surrogate markers for oxidative injury such as mitochondrial protein carbonylation and hepatic 3-
nitrotyrosine content
27
. Using a direct intravital fluorescence-based method
25
 it was confirmed that MitoQ 
reduces hepatocyte oxidative stress early after I/R. In addition, MitoQ has already been usedemployed in 
phase II studies and has for instance reducedwhere it curtailed transaminase levels in patients with 
hepatitis C
43
C
49
, which is an encouraging follow -up to the preclinical notion that MitoQ is generally well-
tolerated and not toxic
44
toxic
50
. The clinical investigation and implementation of mitochondria-targeted 
antioxidants such as MitoQ therefore is an attainableseems a realistic objective. 
  Several limitations of the current study should be considered when interpreting the 
results. The observational nature of the current study means that it is neither designed nor powered to 
detect differences in clinical outcomes. The similarity in post-operative hepatocellularliver injury 
parameters between the I/R and control group (Table 2) therefore does not mean that liver ischemia is 
innocuous, but that VIO in experienced hands is a safe salvage procedure when used to counteract the 
harms of excessive blood loss. The relatively favourablefavorable post-operative transaminase and 
bilirubin values recorded in the I/R group also relates to the fact that only patients with sufficient (future) 
remnant liver size and function are eligible for major liver resection. This is supported by the fact that the 
noted extent of liver injury (i.e., ALT release) is comparable to previous clinical liver I/R cohorts
51,52
. The 
interpretation of the clinical data is further hindered by the inability to separate the contribution of ischemic 
liver injury from the effects of surgical trauma on postoperative DAMP release. It has for instance been 
reported that the DAMP ATP is released from the resection plane after partial hepatectomy
26
. In the latter 
study, patients were not exposed to ischemia during liver resection. Also, the duration of liver surgery and 
hepatic manipulation during surgery both influence the release of liver injury markers
45
markers
53
. The 
longer operating time and trend towards more extensive resections in the I/R group (Table 1) may 
therefore also add to the higher HMGB1 levels in the I/R group rather than VIO use only., although this 
does not per se disqualify the conclusions when contextualized to the mouse data. Last, it should be 
noted that, in line with available evidence
54
, the majority of patients were operated using intermittent VIO 
(Table S4). This technique allows for brief periods of parenchymal (re)perfusion in between cycles of liver 
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ischemia. In contrast, most animal models of hepatic I/R, including ours, employ continuous liver 
ischemia. As the anoxic period primes mitochondria for the post-ischemic burst of ROS production
6
, it is 
conceivable that intermittent VIO lessens the extent of mitochondrial oxidative injury after I/R. 
Accordingly, it also means that it remains to be shown whether I/R injury resulting from intermittent VIO is 
amenable to treatment with mitochondria-targeted antioxidants such as MitoQ.  
 In conclusion, it is shown that HMGB1 release is related to clinical liver I/R injury. The finding that 
the mitochondria-targeted antioxidant MitoQ limited HMGB1 release and reduced I/R injury in mice may 
pave the way for the clinical use of targeted antioxidants against early-onset radicals and oxidants to 
attenuate hepatic I/R injury.  
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7. Figure legends 
 
 
Figure 1. DAMP release and neutrophil activation after clinical liver I/R 
A-D show plasma levels (median±IQR) of the DAMPs HMGB1, nucleosomes, and mtDNA, and the 
marker for neutrophil activity E-AT at 1 h and 6 h after liver surgery in patients. Note that the y-axes are 
scaled logarithmically. E-AT=elastase-1-antitrypsin complex; HMGB1=high mobility group box 1; 
mtDNA=mitochondrial DNA. # indicates p<0.05 versus t=0.  
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Figure 2. HMGB1 release correlates to postoperative liver injury after major liver resection 
A-D show systemic DAMP levels (median±IQR) for patients operated with VIO (I/R, red) or without VIO 
(control, blue). E-F display the correlation between circulating HMGB1 and liver ischemia time and the 
post-operative hepatocellular injury peak. The dashed lines indicate the 95% confidence interval of the 
regression line. Additional correlation data are presented in Supplemental Figures S3. # indicates p<0.05 
versus t=0 in the I/R group, $ indicates p<0.05 versus t=0 in the control group, and * indicates p<0.05 
between the groups indicated by the solid line. ALT=aspartate alanine aminotransferase; E-AT=elastase-
1-antitrypsin complex; HMGB1=high mobility group box 1; I/R=ischemia/reperfusion; IQR=interquartile 
range; mtDNA=mitochondrial DNA; VIO=vascular inflow occlusion. 
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Figure 3. MitoQ attenuates hepatic I/R injury in mice by suppressing HMGB1 release 
A shows the dose-response relationship between MitoQ and hepatocellular injury. The 1 mg/kg MitoQ 
dosage was used in all subsequent experiments (solid line). B demonstrates that MitoQ mitigated hepatic 
oxidative stress during early reperfusion as measured by real-time in vivo microscopy/spectroscopy. C-D 
show that MitoQ decreased ALT release and hepatocellular necrosis at 24 h reperfusion whereas redox-
inactive MitoQ (dTPP) was not protective (also see Fig. S4). E-F indicate that MitoQ attenuated HMGB1 
release but did not affect intracellular HMGB1 levels. G demonstrates that reconstitution of disulfide 
HMGB1 reverses the protective effects of MitoQ. H-I show that MitoQ decreased expression of the 
leukocyte receptor VCAM-1 but did not affect ICAM-1 expression. The heat map (J) depicts a decrease 
(blue) or increase (red) in plasma cytokine concentration in MitoQ-treated animals subjected to I/R versus 
vehicle-treated animals subjected to I/R. The dots indicate a statistically significant difference between the 
MitoQ and control group. Full hepatocellular damage and cytokine results are included in Supplemental 
FiguresFigure S5-7 and Supplemental Table S6 and a functional description of measured cytokines is 
included in Supplemental Table S3. Results are shown as mean±SEM, except for D (median±range). 
Western blot results are presented as densitometric analysis. One representative blot per group is 
included per graph. Group sizes are ≥6 animals/group, except for B (3-4 mice/group). Area under the 
curve analysis was used to assess differences in ROS production (B). * indicates p<0.05 in the MitoQ 
versus the I/R group. au=arbitrary unit; ALT=aspartate alanine aminotransferase; CDCF=5(6)-carboxy-
dichlorofluorescein; dTPP= decyl-triphenylphosphonium; ROS=reactive oxygen species; HMGB1=high 
mobility group box 1; ICAM-1=intercellular adhesion molecule 1; VCAM-1=vascular cell adhesion 
molecule 1. 
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 CTRL (N=13) I/R (N=26) p-value 
Age (years, median ± IQR) 62 (45 – 73) 66 (53 – 70) 0.670 
Gender, male (n, %) 8 (62) 18 (69) 0.725 
BMI (median ± IQR) 25.2 (22.9 – 26.3) 23.9 (20.9 – 26.8) 0.418 
ASA score (n, %) 
 
 
I 
II 
III 
3 (23) 
10 (77) 
0 (0) 
6 (23) 
14 (54) 
6 (23) 
0.153 
Diagnosis (n, %) 
 
 
 
 
 
CRC metastasis 
PHCC 
IHCC 
HCC 
Benign 
Other 
1 (9) 
3 (23) 
2 (15) 
2 (15) 
3 (23) 
2 (15) 
4 (15) 
13 (50) 
2 (8) 
3 (12) 
3 (12) 
1 (3) 
0.132 
Preoperative chemotherapy, yes (n, %) 2 (15) 4 (15) 1.000 
Biliary drainage, yes (n, %) 3 (23) 9 (35) 0.714 
PVE, yes (n, %) 1 (8) 1 (4) 1.000 
ALT baseline, U/L (median ± IQR) 30 (25 – 52) 53 (24 – 71) 0.294 
AST baseline, U/L (median ± IQR) 32 (28 – 52) 45 (28 – 73) 0.178 
Total bilirubin baseline, uM/L (median ± IQR) 9 (6 – 14) 7 (5 – 14) 0.471 
INR baseline (median ± IQR) 1.0 (1.0 – 1.1) 1.0 (1.0 – 1.1) 0.676 
 
Table 1. Baseline characteristics 
Shown are the baseline characteristics of the control (CTRL) and ischemia/reperfusion (I/R) groups.  
ALT=alanine aminotransferase; ASA=American Society of Anesthesiologists; AST=aspartate 
aminostransferase; BMI=body mass index; CRC=colorectal cancer metastases; HCC=hepatocellular 
carcinoma; IHCC=intrahepatic cholangiocarcinoma; INR=international normalized ratio; IQR=interquartile 
range; PHCC=perihilar cholangiocarcinoma; PVE=portal vein embolizationCategorical data were 
analyzed using Fisher’s exact test (binary data) and Chi-square test (>2 variables). Differences between 
numerical variables were assessed using student’s t-tests. 
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 CTRL (N=13) I/R (N=26) p-value 
Resected segments
#
 (%)   0.131 
 3 6 (46.2%) 5 (19.2%)  
 ≥4 7 (53.8%) 21 (80.8%)  
Resection time, min (medianIQR) 59 (41.5 – 71.5) 82 (60 – 130) 0.006 
Duration of ischemia
&
 min (medianIQR) N/A 48 (31 – 68)  
Duration of surgery, min (medianIQR) 306 (261 – 373.5) 460 (380 – 503) 0.001 
Transfusion requirement, units (%)   0.455 
 0 9 (62.9) 12 (48)  
 1-2 2 (15.4) 6 (24)  
 ≥3 2 (15.4) 7 (28)  
Hospital stay, days (medianIQR) 9 (7.5 – 11) 11.5 (8 – 22) 0.036 
Grade III-V complications
@
 (%) 7 (53.8) 13 (52) 1.000 
ICU admission (%) 3 (23.1) 7 (26.9) 1.000 
In-hospital mortality (%) 1 (7.7)  2 (8.0) 1.000 
Peak ALT, U/L (medianIQR) 273 (142.5 – 641.5) 456 (289 – 784) 0.152 
Peak INR (medianIQR) 1.19 (1.12 – 1.31) 1.30 (1.17 – 1.41) 0.411 
Peak total bilirubin, mol/L (medianIQR) 17 (14 – 34) 32 (19 –47) 0.129 
 
 
Table 2. Clinical outcomes. 
# Designates the number of resected Couinaud liver segments. & Patients were subjected to continuous 
or intermittent vascular inflow occlusion as specified in Supplemental Table S4. Details on the resected 
liver segments can be found in Supplemental Tables S4 and S5.  @ Complications were scored 
according to the Clavien-Dindo classification 
1314
. A histopathological assessment of the resection 
specimens is included in Supplemental Table S4. CTRL=control group; I/R=ischemia/reperfusion group; 
ALT=aspartate alanine aminotransferase; ICU=intensive care unit; INR=international normalized ratio; 
IQR=interquartile range; min=minutes. Categorical data were analyzed using Fisher’s exact test (binary 
data) and Chi-square test (>2 variables). Differences between numerical variables were assessed using 
student’s t-tests. 
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 CTRL (N=13) I/R (N=26) p-value 
Age (years, median ± IQR) 62 (45 – 73) 66 (53 – 70) 0.670 
Gender, male (n, %) 8 (62) 18 (69) 0.725 
BMI (median ± IQR) 25.2 (22.9 – 26.3) 23.9 (20.9 – 26.8) 0.418 
ASA score (n, %) 
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II 
III 
3 (23) 
10 (77) 
0 (0) 
6 (23) 
14 (54) 
6 (23) 
0.153 
Diagnosis (n, %) 
 
 
 
 
 
CRC metastasis 
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Benign  
Other 
1 (9) 
3 (23) 
2 (15) 
2 (15) 
3 (23) 
2 (15) 
4 (15) 
13 (50) 
2 (8) 
3 (12) 
3 (12) 
1 (3) 
0.132 
Preoperative chemotherapy, yes (n, %) 2 (15) 4 (15) 1.000 
Biliary drainage, yes (n, %) 3 (23) 9 (35) 0.714 
PVE, yes (n, %) 1 (8) 1 (4) 1.000 
ALT baseline, U/L (median ± IQR) 30 (25 – 52) 53 (24 – 71) 0.294 
AST baseline, U/L (median ± IQR) 32 (28 – 52) 45 (28 – 73) 0.178 
Total bilirubin baseline, uM/L (median ± IQR) 9 (6 – 14) 7 (5 – 14) 0.471 
INR baseline (median ± IQR) 1.0 (1.0 – 1.1) 1.0 (1.0 – 1.1) 0.676 
 
Table 1. Baseline characteristics 
Shown are the baseline characteristics of the control (CTRL) and ischemia/reperfusion (I/R) groups.  
ALT=alanine aminotransferase; ASA=American Society of Anesthesiologists; AST=aspartate 
aminostransferase; BMI=body mass index; CRC=colorectal cancer metastases; HCC=hepatocellular 
carcinoma; IHCC=intrahepatic cholangiocarcinoma; INR=international normalized ratio; 
IQR=interquartile range; PHCC=perihilar cholangiocarcinoma; PVE=portal vein 
embolizationCategorical data were analyzed using Fisher’s exact test (binary data) and Chi-square 
test (>2 variables). Differences between numerical variables were assessed using student’s t-tests. 
 
 
Table 1
  CTRL (N=13) I/R (N=26) p-value 
Resected segments
#
 (%)   0.131 
 3 6 (46.2%) 5 (19.2%)  
 ≥4 7 (53.8%) 21 (80.8%)  
Resection time, min (medianIQR) 59 (41.5 – 71.5) 82 (60 – 130) 0.006 
Duration of ischemia
&
 min (medianIQR) N/A 48 (31 – 68)  
Duration of surgery, min (medianIQR) 306 (261 – 373.5) 460 (380 – 503) 0.001 
Transfusion requirement, units (%)   0.455 
 0 9 (62.9) 12 (48)  
 1-2 2 (15.4) 6 (24)  
 ≥3 2 (15.4) 7 (28)  
Hospital stay, days (medianIQR) 9 (7.5 – 11) 11.5 (8 – 22) 0.036 
Grade III-V complications
@
 (%) 7 (53.8) 13 (52) 1.000 
ICU admission (%) 3 (23.1) 7 (26.9) 1.000 
In-hospital mortality (%) 1 (7.7)  2 (8.0) 1.000 
Peak ALT, U/L (medianIQR) 273 (142.5 – 641.5) 456 (289 – 784) 0.152 
Peak INR (medianIQR) 1.19 (1.12 – 1.31) 1.30 (1.17 – 1.41) 0.411 
Peak total bilirubin, mol/L (medianIQR) 17 (14 – 34) 32 (19 –47) 0.129 
 
 
Table 2. Clinical outcomes. 
# Designates the number of resected Couinaud liver segments. & Patients were subjected to 
continuous or intermittent vascular inflow occlusion as specified in Supplemental Table S1.  
@ Complications were scored according to the Clavien-Dindo classification [Dindo 2004]. A 
histopathological assessment of the resection specimens is included in Supplemental Table 
S4. CTRL=control group; I/R=ischemia/reperfusion group; ALT=aspartate alanine 
aminotransferase; ICU=intensive care unit; INR=international normalized ratio; 
IQR=interquartile range; min=minutes. Categorical data were analyzed using Fisher’s exact 
test (binary data) and Chi-square test (>2 variables). Differences between numerical variables 
were assessed using student’s t-tests. 
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SUPPLEMENTARY MATERIALS AND METHODS 
 
S1.1 Histological assessment of surgical resection specimens 
Liver tissue from the surgical resection specimen was harvested at a distance of the tumor site and 
processed for histological analysis as part of routine clinical care. Histological analysis was performed by 
a hepatopathologist (JV). Due to the known heterogeneity in parenchymal status between the resected 
liver and the remnant liver. in particular in patients with hilar cholangiocarcinoma. the results of the 
histopathological analysis are presented in a descriptive manner in Supplemental Table S2. 
 
S1.2 Intravital spinning disc confocal microscopy of neutrophil dynamics after mouse liver I/R 
Experiments were approved by the animal ethics committee of the University of Calgary (protocol #AC12-
0162) and all animals were treated in accordance with
1
. Male C57BL/6J mice (N = 14. Charles River. 
Montreal. Quebec. Canada) weighing between 20-26 g were housed under standard laboratory 
conditions with unrestricted access to chow and water. The animals were acclimated for at least 2 d 
before entering the experiment. Surgical and intravital imaging procedures were as described
2
. Antibodies 
and MitoQ were added to sterile 0.9% NaCl (B. Braun Melsungen. Melsungen. Germany) to a final 
infusion volume of 100 μL. The used antibodies and antibody concentrations were: sinusoidal endothelial 
cells: rat anti-mouse CD31-PE. 10 μL of 200 μg/mL (cat. # 12-0311-83. clone 390. eBioscience. San 
Diego. CA); neutrophils: rat anti-mouse Ly-6G (Gr-1)-Alexa Fluor 647. 10 μL of 500 μg/mL (cat. # 127610. 
clone 1A8. BioLegend). The mixture was infused into the penile vein immediately before surgery. Hepatic 
I/R was subsequently induced as described in the Materials and Methods section of the main text.  
Intravital spinning disco confocal microscopy was performed with a Quorum Wave FX-X1 spinning disk 
confocal system as described in
2
. The following emission filters were used for the antibody-conjugated 
fluorophores: 593 ± 40 (CD31-PE) and 692 ± 40 (Gr1-Alexa Fluor 647). respectively. Imaging was 
performed with an Olympus UPlanFL-N. 10×. NA = 0.2 objective. The hardware settings were kept 
constant during all experiments (PE channel: laser power 71. exposure time 120 ms. camera gain 1. 
camera sensitivity 224; Alexa Fluor 647 channel: laser power 100. exposure time 120 ms. camera gain 1. 
camera sensitivity 174). Image acquisition was performed under Volocity software control (Version 6.3.1. 
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Perkin Elmer. Waltham. MA). Image acquisition was performed for 1 min at a frame rate of 13 Hz per 
fluorescence channel after the start of reperfusion (the time interval between clip removal and image 
acquisition was on average 4 min) and at t = 4 + 15. 30. 45. 60. 75. and 90 min reperfusion. The number 
of neutrophils per field of view was manually counted using ImageJ/FIJI (NIH. Bethesda. MD) software.  
 
S1.3 Non-invasive whole body imaging of intrahepatic neutrophil elastase activity 
Non-invasive whole body imaging was performed using an InVivoXtreme 4MP (BRUKER. formerly 
Carestream. USA). Mice were shaved and depilated 24 h prior to imaging. Neutrophils were labelled 4 h 
prior to imaging via tail vein injection using Neutrophil Elastase 680 FAST (Perkin Elmer) according to the 
manufacturer’s protocol (4 nmol dye/mouse in 100l of saline) and visualized using 650 nm excitation 
and 700 nm emission wavelength filters. Mice were imagined ventrally from 30 min until 90 min post I/R 
with or without MitoQ treatment in 5-min intervals. In addition. animals were imaged 24 h post-I/R. During 
the whole imaging procedure the mice where anesthetized with isoflurane and kept at 37 
o
C in a 
ventilated imaging chamber. The imaging protocol for each time point contained three steps: 1. 
reflectance imaging (2 s exposure time). 2. fluorescence imaging at 650/700 nm (4 s exposure time). and 
3. X-ray imaging (10 s exposure time). The imaging protocol for each 25-degree angle of the 360-degree 
spin contained two steps: 1. Fluorescence imaging at 650/700 nm (2 s exposure time) and 2. X-ray 
imaging (10 s exposure time). Images were quantified with Bruker molecular imaging software (version 
7.1.3.20550) using a constant ventral region of interest for all animals that covered the upper ventral 
abdominal area in the anatomical region of the murine liver. 
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SUPPLEMENTARY FIGURES AND RESULTS 
 
 
Figure S1 – CONSORT study flow chart  
 
  
Enrolled (n=74) 
Excluded (n=35) 
 Unresectable disease during surgical 
exploration (n=30) 
 Withdrawal of informed consent 
(n=1) 
 Minor liver resection (n=3) 
 Other primary surgeon (n=1) 
Analyzed (n=26. all patients) 
Allocated to I/R group (n=26) 
 Intermittent or continuous vascular inflow 
occlusion 
 At least 1 cycle of 20 min ischemia 
Allocated to control group (n=13) 
 No vascular inflow occlusion 
Analyzed (n=13. all patients) 
=  ) 
Allocation 
Analysis 
Jan 2012 – Dec 2014 Potentially eligible (n=77) 
 
Unwilling to participate (n=3) 
Surgery 
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Figure S2. Plasma cytokine and chemokine levels after clinical liver I/R  
 
Cytokine and chemokine signalling has been extensively studied in pre-clinical liver I/R models
3
 but data 
on the (early) release of pro-inflammatory mediators following clinical liver I/R are scarce. 
A shows that the increase in the cytokine interleukin (IL)-6 was more pronounced in the I/R group at 1 h 
of reperfusion than in the control group. This difference was not detectable at 6 h of reperfusion. B 
indicates that the anti-inflammatory cytokine IL-10 increased in both study groups during the first 6 h of 
reperfusion. without intergroup differences. C and D indicate that the monocyte chemoattractant CCL2 
and neutrophil chemoattractant IL-8 are released into the circulation immediately following major liver 
resection. irrespective of the intraoperative use of liver I/R. In contrast. an early (i.e.. at 1 h of reperfusion) 
but transient rise in plasma IL-12 and IL-1 levels was only noted in the I/R group. whereas this response 
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was delayed until 6 h after surgery in the control group (E-F). Last. G shows that plasma levels of TNF 
remained at baseline in both study arms during the entire study period. which not only contradicts a large 
body of pre-clinical I/R literature. but is also surprising given the importance of TNF in stimulating liver 
regeneration following partial hepatectomy
4,5
. The functional relevance of these differences in the release 
of cytokines between patients subjected to major hepatectomy with and without VIO remains to 
elucidated experimentally. Plasma cytokine levels were measured as described in the main text and 
normalized to plasma total protein content to correct for peroperative hemodiluation
6
. Intragroup 
differences between the three time points were analysed using a repeated measurements ANOVA 
(normally distributed data) or a Friedman test (non-normal data). Differences between the VIO and control 
group at a given time point (intergroup differences) were assessed using a student’s t-test (normally 
distributed data) or Mann Whitney U-test (non-normal data). See the main text for additional details. # 
indicates p<0.05 versus t=0 in the VIO group. $ indicates p<0.05 versus t=0 in the control group. and * 
indicates p<0.05 between the study groups indicated by the solid line. CCL2 = chemokine (C-C motif) 
ligand 2; IL-1 = interleukin 1 beta; IL-8 = interleukin 8; IL-12 = interleukin 12; TNF = tumour necrosis 
factor alpha; VIO = vascular inflow occlusion 
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Figure S3.  The duration of liver ischemia and post-operative liver injury markers do not correlate to 
neutrophil activation. IL-6 release. or IL-10 release in clinical liver ischemia/reperfusion injury 
 
 
It was shown in Figure 1 of the main text that DAMPs (i.e.. HMGB1 and nucleosomes) and cytokines (i.e.. 
IL-6 and IL-10) are released into the circulation following major liver surgery. Of the measured 
parameters. only plasma HMGB1 and IL-6 concentrations increased more profoundly in patients exposed 
to I/R (i.e.. the VIO group) than in the control group (Figure 1E and I). More importantly. postoperative 
plasma HMGB1 levels correlated positively to the duration of liver ischemia and postoperative ALT 
release (Figure 1K and L). indicating that HMGB1 release is not only characteristic for ischemic liver 
injury. but also reflects the extent of parenchymal liver injury. Shown here are the same correlation 
analyses for the pro-inflammatory and/or mitogenic cytokines IL-6. IL-1. and IL-12. the anti-inflammatory 
cytokine IL-10
7,8
. and the marker for neutrophil activation E-AT
9
. It is shown that. in contrast to HMGB1. 
the release of IL-6. IL-12. and IL-10 and the formation of E-ATs do not correlate to the duration of 
ischemia or postoperative ALT values. A weak association was observed between peak IL-12 and peak 
ALT levels (F) and a moderate association was observed between peak IL-1 levels and poster-operative 
ALT release (H). These parameters are therefore likely non-specific inflammatory markers released or 
formed in response to gross surgical trauma (i.e.. liver resection). and. as such. probably hold little 
prognostic potential. Plasma E-AT and cytokine levels were measured as described in the main text. 
Correlations were assessed using Spearman’s r and a p-value <0.05 was considered statistically 
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significant. ALT = aspartate alanine aminotransferase; IL-10 = interleukin 10; IL-6 = interleukin 6; HMGB1 
= high mobility group box 1; E-AT = elastase-1-antitrypsin complexes.  
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Figure S4. MitoQ reduces hepatocellular necrosis at 24 h of reperfusion following mouse liver I/R. 
 
 
Shown are representative hematoxylin and eosin-stained histological slides of mouse livers harvested 24 
h after 30 min of liver ischemia. Images were obtained with a 10x objective. Animals were either treated 
with sterile saline (vehicle. panel A) or 1 mg/kg of the mitochondria-targeted antioxidant MitoQ dissolved 
in sterile saline (panel B). A small area of remaining viable hepatocytes is encircled in white in panel A. 
indicating severe hepatocellular necrosis in I/R-subjected mice. In contrast. panel B shows only small 
patches of confluent necrosis. demarcated in white. at the same time point in MitoQ-treated animals 
(panel B). reflecting reduced hepatocellular necrosis in the MitoQ group. Histological quantification of 
necrotic areas per study arm is shown in Figure 3 of the main text. 
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Figure S5 – Hepatocellular injury peaks 6 h after partial liver ischemia in mice 
 
 
Shown is hepatocellular injury (ALT release. y-axis) plotted as a function of reperfusion time (x-axis) 
following partial liver ischemia in mice. ALT values were normalized to the ALT peak values (i.e.. the 6 h 
reperfusion time point). It should be noted that these data were generated in preliminary experiments with 
a more severe liver I/R model (60 min of ischemia) than is used in the main text (30 min ischemia). 
Besides the duration of ischemia. all experimental procedures were as described in the Materials and 
Methods section of the main text.  
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Figure S6.  MitoQ does not influence the number of Gr-1-positive leukocytes circulating in the hepatic 
microvasculature during early reperfusion after mouse liver ischemia.  
It was proposed in the main text that MitoQ ameliorates hepatic I/R injury by reducing ROS-mediated 
parenchymal cell death during the first minutes of reperfusion and. thereby. suppressing the release of 
pro-inflammatory HMGB1. The premise is supported by the reduction in I/R injury at 6 h and 24 h of 
reperfusion (main text). Because ROS can also propagate sterile inflammation by directly influencing 
leukocyte function
10
 and MitoQ is also taken up by leukocytes. intravital spinning disk confocal 
microscopy was used to investigate whether MitoQ treatment influenced the number of neutrophils 
circulating in early post-ischemic mouse livers. These experiments served to exclude an immediate and 
early effect of MitoQ on neutrophil behaviour (i.e.. preceding the injury peak at 6 – 24 h of reperfusion) 
that could confound the premises raised in the main text. Shown are representative snapshots of 
leukocytes (in green. stained with anti-Gr1 antibodies) circulating in mouse sinusoids (in blue. stained 
with anti-CD31 antibodies).  The number of GR-1-positive leukocytes per field of view (FOV) per time 
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point was manually counted for each animal. The traces per group are shown in the bottom panel of the 
figure.  
 As is shown in top row. sham surgery and manipulation of the mouse liver per se do not increase 
the number of Gr-1-positive leukocytes circulating in the liver microvasculature. In contrast. the number of 
Gr-1-positive leukocytes that pass through the liver rises steadily the first 90 min after I/R (middle row). 
Treatment with MitoQ (1 mg/kg) did not affect the number of circulating Gr-1-positive leukocytes during 
the fist 90 min of reperfusion. indicating that the protective effects of MitoQ noted in Figure 3 of the main 
text are not attributable to direct effects on leukocyte trafficking. These data therefore support the premise 
raised in the main text that reducing oxidative injury in hepatocyte mitochondria during early reperfusion 
reduces the I/R injury peak. which follows several hours later. by limiting the release of HMGB1 and 
neutralizing early innate immune alarm signals. The experimental procedures are described in section 
S1.1.  
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Figure S7. MitoQ transiently increases neutrophil presence during early reperfusion after mouse liver 
ischemia 
 
  
In extension of the intravital imaging of leukocyte accumulation 
(Fig. S7). neutrophil presence was additionally investigated 
during early (30-90 min. panel A) and late (24 h. panels B and 
C) reperfusion using non-invasive whole body fluorescence 
imaging in mice. Counterintuitively. elastase activity was higher 
during early reperfusion in MitoQ-treated animals (N=3. blue 
trace. mean±SEM) than in vehicle-treated mice (N=3. red trace. 
mean±SEM). This finding is difficult to rationalize inasmuch as 
the difference in neutrophil presence is already present at 30 
min of reperfusion. but does not increase from that point 
onwards. The latter is surprising given the gradual increment in 
intrahepatic leukocytes numbers seen with intravital microscopy 
shown in Figure 2 and Figure S8. 
 In contrast to the early time point (panel A). the 
elastase signal at 24 h of reperfusion seemed comparable 
between groups or possibly even lower in MitoQ-treated mice 
(bottom 3 animals) than in the I/R group (top 3 animals). These 
data are in line with the improved liver histology and gross 
amelioration of innate immune activity shown in Figure 2 of the 
main text. It should however be noted that the hepatic 
specificity of probe fluorescence was difficult to ascertain in all 
animals at the 24 h time point (panels B and C. liver region 
encircled in black). Fluorescence data were therefore not 
quantified at this time point. All experimental procedures are 
detailed in section S1.2 
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SUPPLEMENTAL TABLES 
Table S1 – Western blot antibodies 
Antibody Manufacturer Cat # Dilution 
-actin Sigma-Aldrich A5441 1:5000 
HMGB1 Abcam Ab18256 1:900 
ICAM-1 R&D Systems AF796 1:500 
Pan-JNK-1/2 Cell Signaling 9258 1:1000 
Phospho-JNK-1/2 Cell Signaling 4668 1:750 
VCAM-1 R&D Systems AF643 1:500 
 
 
 
Supplementary Table S2 – Histopathological assessment of liver resection specimens. Liver tissue was obtained at a distance of the tumor and 
processed for histological analysis as part of routine clinical care. The results are provided in a descriptive manner due to the heterogeneity in 
histopathological profile between the resection specimen and the remnant liver. # lobular inflammation was categorized according to the number of 
inflammatory foci per 100x objective: grade 1 (mild) = 1 focus and grade 2 (moderate) = 2-4 foci.  
Ptn. VIO Diagnosis Lobular 
inflammati
on
#
 
 
Portal 
inflammati
on 
 
Conflue
nt 
necrosi
s  
Macrovesic
ular 
steatosis
 
 
Fibrosis Sinusoi
dal 
dilatatio
n
# 
Other  
1 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
structures 
Grade 2 
(50%) 
 
2 No Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent 5% Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
structures 
Grade 1 
(<33%) 
 
3 Yes Hepatocellular 
adenoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 5% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures  
without bridging 
Grade 1 
(<33%) 
 
4 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures  
without bridging 
Grade 2 
(50%) 
 
5 Yes Proximal 
cholangiocarcinom
a 
Absent Absent Absent <5% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures  
without bridging 
Grade 2 
(50%) 
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6 Yes Intrahepatic 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 20% Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
structures 
Grade 1 
(<33%) 
 
7 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent 5% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
8 Yes Metastasized 
melanoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 5% Minimal 
perioportal 
fibrosis 
Grade 1 
(>33%) 
 
9 No Focal nodular 
hyperplasia 
Absent Grade 1 
(mild) 
Absent Absent Absent Grade 1 
(>33%) 
 
10 No Chronic sclerosing 
cholangitis 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent 5% Biliary cirrhosis Grade 1 
(>33%) 
 
11 No Hepatocellular 
carcinoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(>33%) 
 
12 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Minimal 
perioportal 
fibrosis 
Grade 2 
(50%) 
 
13 No Hepatocellular 
carcinoma 
Grade 2 
(moderate) 
Grade 3 
(severe) 
5% 20% Porto-portal and 
porto-central 
bridging fibrosis 
affecting >50% 
of vascular 
structures 
-  
14 Yes Colorectal liver 
metastases 
Grade 1 
(mild) 
Absent 20% Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
Grade 2 
(50%) 
Signs of nodular 
regenerative 
hyperplasia
11
 caused 
by preoperative 
chemotherapy 
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structures  
without bridging 
(oxaliplatin) 
15 No Intrahepatic 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 5% Absent  Grade 1 
(<33%) 
 
16 No Perihilar 
cholangiocarcinom
a 
Absent Grade 2 
(moderate) 
Absent Absent Porto-portal and 
porto-central 
bridging fibrosis 
affecting >50% 
of vascular 
structures 
Grade 1 
(>33%) 
 
17 Yes Hepatocellular 
adenoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Absent Grade 1 
(>33%) 
 
18 Yes Colorectal liver 
metastases 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 50% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures  
without bridging 
Grade 2 
(50%) 
 
19 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
20 Yes Chronic/recurring 
cholangitis 
Grade 1 
(mild) 
Grade 3 
(severe) 
Absent 5% Biliary cirrhosis 
with briding 
Grade 1 
(<33%) 
 
21 Yes Intrahepatic 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
22 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent Absent Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
Grade 2 
(50%) 
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structures 
23 No Hepatoblastoma Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 2 
(50%) 
 
24 Yes Hepatocellular 
carcinoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
25 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 3 
(severe) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
26 No Intrahepatic 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 3 
(severe) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 3 
(>50%) 
 
27 No Chronic/recurring 
cholangitis 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Periportal and 
minimal 
pericellular and 
perivenular 
fibrosis without 
bridging 
Grade 2 
(50%) 
Purulent cholangitis 
28 Yes Colorectal liver 
metastases 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
Grade 2 
(50%) 
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structures 
without bridging 
29 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent 35% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without bridging 
Grade 1 
(<33%) 
 
30 Yes Hepatocellular 
carcinoma 
Grade 1 
(mild) 
Grade 3 
(severe) 
Absent 20% Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
structures 
Grade 1 
(<33%) 
 
31 Yes Hepatocellular 
carcinoma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Pericellular 
fibrosis affecting 
<33% of 
vascular 
structures 
without bridging 
Grade 2 
(50%) 
 
32 Yes Intrahepatic 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 1 
(mild) 
5% Absent Some periportal 
fibrosis without 
pericellular 
fibrosis or 
bridging 
Grade 2 
(50%) 
 
33 No Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent 5% Some 
periportal/pericell
ular fibrosis 
affecting <33% 
of vascular 
structures 
without briding 
Grade 2 
(50%) 
 
34 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
<5% 5% Bridging porto-
portal fibrosis 
affecting <50% 
of vascular 
structures 
Grade 2 
(50%) 
Signs of lobular 
atrophy 
35 No Colorectal liver 
metastases 
Grade 1 
(mild) 
Grade 1 
(mild) 
<25% 5% Minimal 
periportal/pericell
ular without 
Grade 1 
(<33%) 
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bridging 
36 No Epithelioid 
hemangioendotheli
oma 
Grade 1 
(mild) 
Grade 1 
(mild) 
Absent Absent Minimal 
periportal  
Grade 1 
(<33%) 
 
37 Yes Perihilar 
cholangiocarcinom
a 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent Absent Some periportal 
fibrosis. 
developing 
bridging fibrosis 
Grade 2 
(50%) 
 
38 Yes Perihilar 
cholangiocarcinom
a 
Absent Grade 1 
(mild) 
Absent Absent Discete 
periportal  
Grade 1 
(<33%) 
 
39 Yes Colorectal liver 
metastases 
Grade 1 
(mild) 
Grade 2 
(moderate) 
Absent 35% Periportal Grade 2 
(50%) 
Ballooning. 
borderline 
steatohepatitis. 
several Councilman 
bodies. 
 
Table S3: Functional description of inflammatory messengers measured in mouse plasma.  
Abbreviation Protein  Function Reference 
Tnfα Tumor necrosis factor 
alpha 
Induces macrophage activation. neutrophil 
recruitment. and apoptosis 
12
 
Il-1β Interleukin 1 beta Induces Cox-2 and Icam-1 expression and Il-6 
and chemokine production 
13
 
Il-4 Interleukin 4 Mediates T helper 2 cell differentiation 14,15 
Il-5 Interleukin 5 Stimulates proliferation and activation of 
eosinophils and basophils 
16
 
Il-6 Interleukin 6 Regulates neutrophil recruitment through 
cytokine and chemokine signaling 
17
 
Il-10 Interleukin 10 Inhibits activation of T cells. monocytes. and 
macrophages.  
7,8,18
 
Il-12 Interleukin 12 Activates T-cells and natural killer cells and 
enhances proliferation of hematopoietic 
progenitor cells 
19
 
Il-13 Interleukin 13 Inhibits cytokine production by monocytes and 
regulates Ifn- production by lymphocytes 
20
 
Il-18 Interleukin 18 Suppresses anti-inflammatory cytokines 21 
Il-22 Interleukin 22 Promotes cell proliferation and survival 22 
Ccl5 Chemokine (C-C motif) 
ligand 5 
Regulates activation and chemotaxis of 
leukocytes and lymphocytes 
23,24
 
Gm-csf Granulocyte-macrophage 
colony-stimulating factor 
Governs production. differentiation. 
proliferation. and activation of granulocytes 
and monocytes 
16,25
 
Ifn- Interferon gamma Activates macrophages and promotes T 
helper 1 cell differentiation 
26
 
Baff B cell activating factor Stimulates B cell proliferation and function 27 
Tslp Thymic stromal 
lymphopoietin 
Induces T cell signaling and enhances 
maturation of dendritic cells 
28,29
 
Vegf Vascular endothelial 
growth factor 
Is mitogenic and angiogenic 30,31 
 
This table was adapted from
32
. 
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Table S4 – Duration and technique of vascular inflow occlusion and removed liver segments during major 
liver surgery in patients. 
 
Patient # Cumulative 
ischemia time (min) 
Method of vascular 
inflow occlusion 
Couinaud segments 
removed 
1 50 Intermittent I-IV 
2 50 Intermittent V-VIII 
3 50 Intermittent I+V+VIII+part IV 
4 43 Intermittent I-IV 
5 56 Intermittent I-IV 
6 20 Continuous I-IV 
7 65 Intermittent I-IV 
8 42 Intermittent V-VIII 
9 120 Intermittent II-IV+wedge VI+ VII 
10 52 Continuous II+V+part VIII 
11 76 Intermittent V-VIII 
12 39 Intermittent I-IV 
13 24 Continuous V-VIII 
14 26 Intermittent II-IV 
15 68 Intermittent I-IV 
16 93 Intermittent I-IV + part VIII 
17 68 Intermittent V-VIII 
18 46 Intermittent V-VIII + part IV 
19 20 Continuous V-VIII 
20 72 Intermittent VII-VIII + I 
21 43 Intermittent II-IV 
22 33 Continuous II-IV 
23 30 Continuous V-VIII + I 
24 68 Intermittent I-IV 
25 25 Continuous V-VIII+ I 
26 68 Intermittent I-IV + wedges V+VI+VIII 
 
The table shows the duration of ischemia, the method of vascular inflow occlusion, and the resected 
Couinaud liver segments for all patients included in this study that were subjected to I/R during liver 
resection (i.e.. the I/R group). When excessive intraoperative bleeding occurs during liver resection. the 
afferent vasculature is occluded with a sling to prevent hemodynamic complications. This surgical 
technique is known as vascular inflow occlusion or the Pringle manoeuvre
33
 and induces I/R injury as side 
effect. Intermittent vascular inflow occlusion is the gold standard technique and consists of repetitive 
cycles of 20 min of ischemia followed by 10 min of reperfusion
34
. As is shown in the table. continuous 
ischemia is only used if the anticipated duration of vascular inflow occlusion is short. or if the situation 
does not permit the 10 min reperfusion period normally used in intermittent vascular inflow occlusion 
(e.g.. patient #10). 
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Table S5 –Removed liver segments during major liver surgery in patients operated without vascular 
inflow occlusion (control group). 
  
Patient # Couinaud segments 
removed 
27 II-IV 
28 II-IV 
29 II-IV 
30 II-IV 
31 V-VIII 
32 I-IV 
33 I + V-VIII + part IV 
34 II-IV 
35 I-IV 
36 II-IV 
37 I-IV 
38 V-VIII 
39 V-VIII 
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Table S6 Cytokine levels 6 h and 24 h after sham operation or liver I/R in untreated mice or mice treated 
with MitoQ.  
 
 6 h  
sham 
6 h 
 I/R 
6 h  
MitoQ + I/R 
24 h  
sham 
24 h  
 I/R 
24h  
MitoQ + I/R 
IL-10  1.0 ± 0.3 9.7 ± 7.9 7.0 ± 3.3
#
 1.0 ± 0.3 3.0 ± 1.6 6.3 ± 2.5
#
 
IL-18 134.3 ± 27.4 1034.0  ± 420.0 706.6 ± 163.2 134.3 ± 27.4 749.3 ± 212.7 611.5 ± 156.2 
IL-4 1.0 ± 0.1 4.6 ± 1.5 3.7 ± 0.4 1.0 ± 0.1 4.0 ± 1.2 3.8 ± 1.6 
IL-5 831.4 ± 494.0 900.3 ± 342.3 1669.0 ± 1449.0 831.4 ± 494.0 639.0 ± 567.5 449.1 ± 486.4 
IL-6 831.4 ± 494.0 2396.0 ± 1929.0 915.2 ± 351.3
#
 831.4 ± 494.0 1900.0 ± 1630.0 1229.0 ± 1719.0 
TNF-a 10.0 ± 3.5 92.0 ± 52.6 49.0 ± 10.0
#
 10.0 ± 3.5 58.0 ± 40.4 34.5 ± 26.6 
IL-22 584.6 ± 521.4 4873.0 ± 2018.0 1263.0 ± 1790.0
#
 584.6 ± 521.4 61.2 ± 48.0 42.4 ± 11.2 
TSLP 4.0 ± 3.0 28.3 ± 6.8 25.0 ± 9.5 4.0 ± 2.8 19.1 ± 14.5 21.4 ± 11.1 
BAFF 2166.0 ± 435.6 11141.0 ± 2556.0 10348.0 ± 2354.0 2166.0 ± 435.6 15042.0 ± 3487.0 11754.0 ± 2854.0 
VEGF 12.1 ± 3.5 68.7 ± 12.4 53.4 ± 12.6 12.1 ± 3.5 60.0 ± 16.3 52.8 ± 9.3 
RANTES 21.0 ± 4.0 67.3 ± 10.0 63.5 ± 13.4 21.0 ± 4.0 57.8 ± 10.2 72.2 ± 34.8 
GM-CSF 0.3 ± 0.7 9.5 ± 6.6 3.7 ± 2.4
#
 0.3 ± 0.7 6.6 ± 8.9 2.7 ± 5.2 
IFN-y 2.6 ± 1.1 19.8 ± 13.5 8.8 ± 3.0
#
 2.6 ± 1.1 21.7 ± 32.1 9.0 ± 8.1 
IL-1b 3.8 ± .3 21.4 ± 6.1 15.2 ± 3.6 3.8 ± 1.3 19.6 ± 15.0 15.5 ± 12.2 
IL-12 2.5 ± 0.3 14.2 ± 1.6 10.8 ± 1.5
#
 2.5 ± 0.3 16.1 ± 9.0 11.0 ± 6.0 
IL-13 6.7 ± 0.9 29.4 ± 9.1 24.5 ± 5.9 6.7 ± 0.9 26.3 ± 9.3 19.7 ± 42 
 
All cytokine levels are shown as pg/mL, values represent mean±SD. #  indicates p<0.05 versus the I/R 
group. The materials and methods are included in the main text. The cytokine levels are also shown as 
heat map in Figure 3J of the main text. 
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